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Development of Novel Tools for Radial Glia Lineage Tracing and Modeling Central Nervous 
System Tumors 
Fuyi Chen, PhD 
University of Connecticut, 2014 
 
In this dissertation, I first established a novel non viral piggyBac transposon mediated 
transgenesis approach delivered by in utero electroporation for radial glia lineage tracing. 
Furthermore, I developed a novel central nervous system tumor model in rat using piggyBac IUE. 
By directing expression of oncogenic HRasV12/AKT in radial glia, astrocytes and 
oligodendrocytes, glioblastoma multiforme and anaplastic oligoastrocytoma were induced. Also 
addition of neurogenic bHLH transcription factors Neurogenin 2 and Neural differentiation 1 to 
GBM inducing HRasV12/AKT, malignant pediatric atyical teratoid rhabdoid tumor like tumor 
was induced. These results shad lights on the sources of tumor heterogeneity and indicate that 
oncogenic event occurring in disparate cell types and/or molecular context can lead to different 
tumor formation.  Last, I explored the application of RNA guided genome engineering tool 
CRISPR/Cas9 in studying necortical development and model human neural developmental 
disorder as well as glioblastoma multiforme using CRISPR/Cas9 system. In utero electroporation 
of CRISPR/Cas9 constructs targeting PTEN, successfully knocked out PTEN expression in 
neurons.  PTEN negative neurons showed hypertrophy and decreased resting membrane potential, 
increased sEPSCs and mEPSCs. Combinations of gRNAs targeting PTEN, NF1 and P53 induced 
glioblastoma multiforme.  These new tools shall be proven to be powerful to study neocortical 
development and central nervous system tumors. 
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Chapter 1 Introduction 
 
 
Central nervous system tumor and tumor heterogeneity 
Primary malignant central nervous system (CNS) tumors represent about 2% of all cancers 
but account for a disproportionate rate of morbidity and mortality (Buckner et al., 2007). The 
incidence rate of all primary malignant and non-malignant brain and CNS tumors is 20.6 cases 
per 100,000 (7.3 per 100,000 for malignant tumors and 13.3 per 100,000 for non–malignant 
tumors). The rate is higher in females (22.3 per 100,000) than males (18.8 per 100,000). An 
estimated 24,620 new cases of primary malignant (13,630 in males and 10,990 in females) and 
45,100 new cases of non–malignant brain and CNS tumors are expected to be diagnosed in the 
United States in 2013. An estimated 13,700 deaths will be attributed to primary malignant brain 
and CNS tumors in the United States in 2012 (http://www.cbtrus.org/factsheet/factsheet.html).  
It has been long appreciated that cancers including CNS tumors have extensive cellular and 
genetic diversity. Such high heterogeneity complicates cancer diagnosis, treatment and prognosis. 
The molecular and cellular mechanisms underpinning these heterogeneities remain central 
questions in cancer biology. Extensive genetic and phenotypic diversity exist not only between 
tumors (inter-tumor heterogeneity) but also within individual tumors (intra-tumor heterogeneity) 
(Burrell et al., 2013). Inter-tumor heterogeneity occurs between tumors arising from same organ, 
leading to classification of different tumor subtypes. Intra-tumor heterogeneity occurs within 
individual tumors in which tumor cells often differ in features such as size, morphology, and 
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membrane composition as well as behaviors such as proliferation rate, cell-cell interaction, 
metastatic proclivity, and sensitivity to chemotherapy (Heppner, 1984).  
Cancer stem cells and clonal evolution models have been established to explain intra-tumor 
heterogeneity (Campbell and Polyak, 2007). The cancer stem cell model states that a small 
population of tumor cells serves as the cancer stem cells and drives tumor initiation, progression 
and recurrence.  The clonal evolution model states that cancer cells over time acquire various 
combinations of mutations within a tumor and that genetic drift and stepwise natural selection for 
the fittest, most aggressive cells drive tumor progression(Polyak, 2007, 2011).  Two models have 
been proposed to explain inter-tumor heterogeneity, the genetic mutation model and the cell of 
origin model(Visvader, 2011). In genetic mutation model, oncogenic mutations primarily 
determine tumor phenotype. Different genetic and/or epigenetic mutations cause different tumor 
formation. In the cell of origin model, the cell types that serve as the cell of origin determine 
tumor phenotype. Different tumor types are arising from distinct cells types(Visvader, 2011). 
Understanding the cause of tumor heterogeneity will greatly help to develop more effective 
targeted therapy and new treatment regimen.  
 
 
Development of Neocortex 
Normal tissue development follows pre-determined developmental program from stem cells 
to committed progenitors, which then will generate differentiated cells that constitute the bulk of 
the tissue or organ(Visvader, 2011). Many human diseases including cancers are caused by 
perturbation of this development program.  Understanding developmental hierarchy in normal 
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tissue is essential to understand the etiology of tumors, to pinpoint the sources of tumor 
heterogeneity. The normal lineage developmental order serves a frame work to probe potential 
therapy targets for disease treatment. Brain tumors constitute large proportion of the CNS tumors 
thus in this section the current model for neocortical development is being reviewed. 
Early during neocortical development, pseudostratified neuroepithelium of ectodermal origin 
lining the lateral ventricular walls of mammals function as neural stem cells (NSCs). 
Neuroepithelial cells undergo symmetric division to expand the stem cell pool. When 
neurogenesis begins, neuroepithelial cells start to transform into radial glia cells which serve as 
common progenitors for many cell types in CNS. Radial glia maintain both neuroepithelial 
features such as expression of neuroepithelial marker Nestin (Hartfuss et al., 2001) and apical-
basal polarity (Chenn et al., 1998) as well as astroglia properties such as astrocytes specific 
glutamate transporter (GLAST), glial fibrillary acidic protein (GFAP) (Choi and Lapham, 1978; 
Levitt and Rakic, 1980), vimentin and brain lipid binding protein (BLBP) (Campbell and Gotz, 
2002).  
During cortical neurogenesis, radial glia undergo asymmetric division and generate neurons 
either directly or indirectly through intermediate progenitors (IPCs) (Haubensak et al., 2004; 
Noctor et al., 2004; Noctor et al., 2007).Neuronal IPCs (nIPCs), sometimes referred to as basal 
progenitors, populate a region above the ventricular zone (VZ) called subventricular zone (SVZ), 
which is thought as the major site of neurogenesis (Haubensak et al., 2004; Miyata et al., 2004; 
Noctor et al., 2004; Noctor et al., 2007; Zecevic et al., 2005). nIPCs either undergo symmetric 
division to generate two daughter neurons or divide symmetrically to produce two additional 
IPCs (Haubensak et al., 2004; Kriegstein and Alvarez-Buylla, 2009; Miyata et al., 2004; Noctor 
et al., 2004; Noctor et al., 2007 ).  
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Later during cortical development, most radial glia cells lose their apical contact with 
ventricular surface and migrate toward to cortical plate through somal translocation. During 
somal translocation, radial glia gradually change morphology from bipolar to unipolar and 
eventually take astrocytic morphology with multi polar processes (Choi and Lapham, 1978; 
Noctor et al., 2008; Schmechel and Rakic, 1979; Voigt, 1989). Some astrocytes might go 
through astrocytic IPC stage and divide locally before terminal differentiation (Ichikawa et al., 
1983; Kriegstein and Alvarez-Buylla, 2009; Mares and Bruckner, 1978). At the end of 
embryonic development, a subpopulation of radial glia retains apical contact.  Some of these 
neonatal radial glia convert into ependymal cells. The others convert into adult SVZ astrocytes 
(type B cells) that function as adult neural stem cells and generate olfactory bulb 
interneurons(Kriegstein and Alvarez-Buylla, 2009; Merkle et al., 2007; Merkle et al., 2004). 
Oligodendrocytes are also generated from radial glia during embryonic cortical development 
(Gorski et al., 2002; Kessaris et al., 2006). A population of oligodendrocyte progenitor cells 
(OPCs) is generated by type B cells in SVZ (Aguirre et al., 2007; Levison and Goldman, 1993; 
Menn et al., 2006; Merkle et al., 2004). 
 
Existing methods for labeling and manipulating neural progenitor lineage 
Retroviral vectors have been widely used for tracing radial glia lineage. For example, early 
radial glia lineage tracing experiments using retroviral vectors provided early in vivo evidence 
that radial glia are the common progenitors for neurons and astroglia(Gray and Sanes, 1992; 
Kamei et al., 1998; Walsh and Cepko, 1988, 1993). Combinations of retroviral radial glia 
labeling and time lapse imaging provide definitive in vivo evidence that radial glia give rise to 
neurons and astrocytes(Noctor et al., 2001; Noctor et al., 2002; Tamamaki et al., 2001).Because 
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of the cargo limit, it is difficult to achieve simultaneous labeling and manipulation of lineage 
using retrovirus.  
The RCAS-tva system has also been widely used to trace neural progenitor lineage. It uses 
the avian RCAS (replication-competent avian sarcoma-leukosis virus long terminal repeat with 
splice acceptor)/tumor virus A (TVA). The RCAS virus only transduce cells that express the 
cognate avian retroviral receptor TVA (Orsulic, 2002). For example, Menn etal (Menn et al., 
2006) used the RACS –tva system to label the lineage of SVZ type B cells and found that both 
myelinating and nonmyelinating oligodendrocytes originated from SVZ type B cells. 
 
Radial glia fate labeling experiments have also been performed using transgenic mice with 
developmentally regulated promoter driving Cre/loxp recombination (Anthony and Heintz, 2008; 
Anthony et al., 2004; Murdoch and Roskams, 2008). For example, Anthony and colleagues have 
used transgenic mouse in which Cre recombinase was driven by BLBP promoter to fate label the 
Blbp+ radial glia and demonstrated that radial glia serve as the neural progenitors(Anthony et al., 
2004).  Another study also performed by Anthony et al directly compared the lineage of Blbp+, 
Glast+ and hGFAP+ radial glia subpopulations and found Blbp+Glast+hGFAP- radial glia were 
neurogenic and Blbp+Glast+hGFAP+ were gliogenic in ventral telencephalon(Anthony and 
Heintz, 2008). 
Another elegant genetic lineage labeling approach named Mosaic Analysis With Double 
Marker (MADM) allows for simultaneous labeling and gene knockout in clones of somatic cells 
or isolated single cells in vivo(Liu et al.; Zong et al., 2005). In MADM, Cre-mediated 
interchromosomal recombination results in the generation of complete coding sequence of 
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fluorescent reporter genes and cells generated from same progenitor are labeled with same color. 
Even though effective, it is costly to generate and maintain transgenic mouse lines. 
Table 1 Comparison of existing methods for neural progenitor lineage tracing 
Methods Merits Limitations 
Retrovirus Time-control, 
Permanent 
Differential infectivity 
of cells, 
Potential integration site effects, 
Cargo limit 
RACS-tva system Permanent Dependent on gene/promoter 
expression  
Require transgenic animals 
Labor and cost intensive 
Species dependent  
Tissue-specific 
recombinase 
Noninvasive 
Permanent 
Dependent on gene/promoter 
expression  
Require transgenic animals 
Labor and cost intensive 
Species dependent 
MADM Noninvasive 
Multicolor, 
Permanent, 
Sparse labeling 
Require transgenic animals 
Labor and cost intensive 
Species dependent  
Electroporation 
of DNA 
transposon 
Simultaneously labeling 
and manipulation 
Time control 
Cheaper and faster 
Not species dependent 
Invasive 
Accessibility to cells 
 
Recently, DNA transposons have also been reported to trace and manipulate progenitor 
lineage. For example, Lu et al (Lu et al., 2009) used piggyBac transposon to label and 
manipulate progenitor lineage in chicken spinal cord. Yoshida et al (Yoshida et al., 2010) used 
the Tol2 transposon in mouse to label and manipulate the radial glia lineage.  The relative ease of 
implementation and experimental flexibility of DNA transposon system will make it a valuable 
tool for tracking and manipulating neural progenitor lineage. 
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Animal models for CNS tumors 
Orthotopic Xenograft mouse models, genetically engineered mouse models (GEM) and 
somatic-cell engineered mouse models (SEM) are the main glioma animal models and the 
prevailing model is the SEM.  
Xenograft mouse models are generated by orthotopically implanting human glioma cell lines 
or human tumor cells into immune-compromised mouse. Although they are widely used for 
preclinical testing, histologically, xenograft tumors don't recapitulate human tumors and the 
tumor -host immunoresponse is inhibited (Candolfi et al., 2007; Jones and Holland, 2011).  For 
tumors that genetically engineered mouse models still don’t exist for some tumors such as 
atypical teratoid rhabdoid tumor, group 3 and 4 medullablastoma (Swartling et al., 2013), 
xenograft mouse models provide an alternative approach.  
Genetically engineered mouse (GEM) models are generated by introducing genetic 
abnormalities found in human to mice through either germ-line modification or somatic 
modification. Most frequently used genetic abnormalities used in CNS tumor models include: 
mutated or constitutively active tyrosine kinase receptors (RTKs), mutated components in 
downstream RTKs pathway, loss of function of tumor suppressors or in combinations with each 
other (Swartling et al., 2013). Expression of constitutively active EGFR VIII together with loss of 
function tumors suppressors such as Ink4a/Arf (Persson et al., 2010; Weiss et al., 2003) as well 
as PTEN (Bachoo et al., 2002; Ding et al., 2003; Zhu et al., 2009) in astrocytes induced 
oligodendroglioma and glioblastoma. Another widely used growth factor is platelet-derived 
growth factor receptor beta (PDGFRB), expression of PDGFRB alone or in combination with 
loss of tumor suppressor in different cell types have resulted in oligodendroglioma, glioblastoma 
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formation (Calzolari et al., 2008; Dai et al., 2001; Hede et al., 2009; Lindberg et al., 2009; Shih 
et al., 2004; Uhrbom et al., 1998; Uhrbom et al., 2000). Germ line or somatic cell deletions of 
tumor suppressors have been exploited intensively to model low and high grade glioma  
(Alcantara Llaguno et al., 2009; Jacques et al., 2010; Kwon et al., 2008; Wang et al., 2009; Wei 
et al., 2006; Xiao et al., 2002; Zhu et al., 2005). Many studies have been reported using mutant 
Ras protein, including HRas, VRas and NRas to induce CNS tumors (Abel et al., 2009; Ding et 
al., 2003; Holland et al., 2000; Shannon et al., 2005; Uhrbom et al., 2002; Wei et al., 2006).  
Somatic genetic engineering by recombinant virus allows control of gene expression in 
particular organs, cell types and at specific developmental stages. There are several systems that 
have been reported. A previous study reported the induction of brain tumor by PDGFR-B using 
the replication competent MMLV (Moloney Murine Leukemia Virus) (Uhrbom, et al 1998). 
MMLV can infect all cell types but the tumor cell-of-origin is not determinable in this 
experiment. Another widely used system is the RACS-TVA system (Holland, et al 1998; 
Holland, et al 2000; Uhrbom, et al 2002 ; Hambardzumyan, et al 2009; Holmen, et al 
2005).Recently GFAP-tva (tva expresses in astrocytes) and Nestin-tva (tva expresses in neural 
stem cells) mouse lines are available (Holland, 2000). Adenovirus (Wei, et al 2006; Charest, et al 
2006) and lentivirus (Marumoto, et al 2009) are also used to induce glioma in mouse. More 
recently Wiesner reported (Wiesner, et al 2009) that the Sleeping Beauty transposon can be used 
as a non-viral delivery tool to induce glioma.  
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Table 2 Features of existing CNS tumor models 
Animal models Features 
Orthotopic Xenograft Tumor histology doesn’t resemble human tumors 
Fast  
Genetic Engineered 
Mouse Model (GEM) 
Tumor histology resembles human GBM. Can’t 
distinguish primary mutation and secondary mutation.  
Species dependent. Laborious 
Somatic Engineered 
Mouse Model (SEM) -
Viral vector 
Controlled gene expression in particular organs, cell 
types and at specific developmental stages.  
Clonal origin and migration pattern is difficult to 
track. Not suitable for multigene delivery. 
Somatic Engineered 
Mouse Model (SEM) –
Sleeping Beauty 
transposon 
Similar to viral vector.  
Multigene delivery 
 
Tools for somatic cell transgenesis and genome editing 
Most of human disease including cancers are caused by somatic mutations (Poduri et al.). 
Thus tools for somatic cell transgenesis are exceedingly important for understanding etiology of 
somatic disease. Transposon system and recently discovered CRISPR/Cas9 system have been 
adapted as somatic cell transgenesis tool. For better understanding of both systems, the history 
and background of transposon and CRISPR/Cas are briefly reviewed below. 
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Transposon system 
Transposons, sometimes referred to as transposable elements, also known as “jumping 
genes”, are DNA sequences that move from one location in the genome to another. They were 
first identified in maize by Barbara McClintock. Originally, they were thought to be “junk” in 
the genome. Nowadays it is more and more clear that they have important functions in disease 
development (Miki et al., 1992), driving the evolution of genome as (Koga et al., 2006) well as 
increase genetic diversity (Beck et al.).  There are mainly two classes of transposons: RNA 
transposon and DNA transposon. In the following section I will talk about the features of DNA 
transposons that make it a valuable tool for genetic studies; the currently widely used Tol2, 
Sleeping Beauty and piggyBac transposon as well as their related transposon plasmid system. 
DNA transposons 
DNA transposons transpose through cut and paste mechanism: the transposon encoded 
transposase excises the transposon from its original location and integrates it into elsewhere in 
the genosme (Ivics et al., 1997; Plasterk, 1996). In order to transpose, transposons should consist 
two essential components: an enzyme, namely tranposase, that work in trans to excise tranposon 
from original location and reintegrate it elsewhere in the genome and DNA sequences that work 
in cis, are recognized and mobilized by transposase. These sequences are usually found in the 
terminal repeats of transposon and are required for transposition in the presence of a 
complementary transposase(Ivics et al., 1997). Transposons can be classified as autonomous and 
nonautonomous transposons. Autonomous transposons encode active transposase, and are 
capable of transposition on their own. The non autonomous transposons do not express active 
transposase but retain DNA sequences that are necessary for transposition. This feature makes 
transposon system a valuable tool for integrating DNA sequences into chromosomes (Ivics et al., 
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1997).  Many DNA transposons have been utilized as powerful genetic tools such as the P 
elements in Drosophila (Cooley et al., 1988) and the Tc1 element in Caenorhabditis elegans 
(Plasterk, 1996). Tol2, Sleeping Beauty and piggyBac transposon are recently discovered or 
resurrected and have been shown to be powerful tools for cellular transgenesis. 
Tol2 transposon 
Tol2 transposon was identified from the genome of medaka fish (Oryzias latipes) (Koga et al., 
1996) and is the only autonomously active transposon in hTA transposon family (Kawakami et 
al., 1998; Koga et al., 1996). Structurally, it is about 4.7kb in length and contains a 649 amino 
acids transposase protein.  Tol2 randomly transpose within the genome and upon transposition an 
8bp duplication is created (Kawakami et al., 2000). 200bp and 150bp minimal sequence which 
contains 12bp inverted terminal repeats have been discovered embedding in the left and right 
ends of Tol2 transposon (Urasaki et al., 2006). Any foreign DNA fragments that are cloned 
between these sequences can integrate in to host genome in the presence of Tol2 tranposase. It 
has been shown that Tol2 vectors can carry 11kb cargo without affecting the transposition 
efficiency (Urasaki et al., 2006). Tol2 transposon system has been successfully applied in many 
model organisms including zebra fish, chicken and mouse (Kawakami, 2007). 
Sleeping Beauty Transposon  
Even though DNA transposons have been isolated in many species including fish, Xenopus 
and human (Ivics et al., 1996; Koga et al., 1996; Oosumi et al., 1995) , almost no autonomous 
transposon has been isolated from vertebrate, except the Tol2 transposon mentioned above. 
These transposons are not functional due to mutations in transposase coding sequence caused by 
a process named "vertical inactivation" (Ivics et al., 1997; Lohe et al., 1995). Many efforts have 
been made to reconstruct active DNA transposon from non functional inactive transposons by 
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engineering the coding sequence of transposase. In 1997, Ivics et al used accumulated 
phylogenetic data to reconstruct a transposase gene of Tc1 like transposon from salmonid 
subfamily. This transposon system was wakened from a long evolutionary sleep; thus they 
named the resulted active transposase Sleeping Beauty (Ivics et al., 1997). 
Since its resurrection, the features of Sleeping Beauty transposon (SB) have been explored. 
Structurally SB is 1.6kb in length and consists of SB transposase coding region along with two 
approximately 230bp long inverted repeats containing the minimal sequences for transposition.  
Similar to Tol2, the SB transposase gene can be physically separated from the inverted repeats 
and replaced with other DNA sequence (Izsvak and Ivics, 2004).  The cargo limit for SB is 
around 10kb (Izsvak et al., 2000). Like other transposons in Tc1/mariner family, SB 
preferentially integrate into TA dinucleotide that is duplicated during insertion (Ivics et al., 1997; 
Plasterk, 1996). A 3 bp "footprint" is left in the genome when SB is excised (Luo et al., 1998). 
SB also exhibits a phenomenon called "overproduction inhibition" which means once SB 
transposase exceeds the optimal concentration, increase in the amount of transposase will 
decrease transposition activity(Belur et al., 2003; Lohe and Hartl, 1996). SB has been widely 
used in insertional mutagenesis (Carlson and Largaespada, 2005; Dupuy, 2010), generating 
transgenic animals (Ivics and Izsvak, 2005)and gene therapy(Izsvak and Ivics, 2004). Albeit 
powerful, there are several aspects, for instance, low cargo capacity and low transposase activity, 
need to be improved  Many progresses have been made in improving SB including increasing SB 
transposase activity by construction hyperactive SB transposase (Mates et al., 2009; Zayed et al., 
2004) as well as increasing the cargo capacity(de Silva et al., 2010). Garrison et al reported the 
postintegrative gene silencing within Sleeping Beauty transposon system (Garrison et al., 2007). 
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It has been reported that cHS4 can prevent SB delivered transgene cassette from silencing 
(Dalsgaard et al., 2009; Sharma et al., 2012). 
 
PiggyBac transposon 
PiggyBac (PB) transposon, formerly named as IFP2, was first isolated from the genome of a 
cabbage looper moth Trichoplusia ni (Fraser, et al 1995). Structurally, it is 2472 bp in length and 
has a 2.1 kb open reading frame, encoding 549 amino acids 68kD transposase PBase (Elick et al., 
1996). The piggyBac transposon has been engineered into a binary system that consists of two 
plasmids: the helper plasmid, providing the enzyme, piggyBac transposase (PBase), which 
catalyzes transposition and a donor plasmid, providing the recognition sequence, the transgene 
for insertion and the terminal repeats (TR) of the transposase. DNA fragments or genes of 
interest that are flanked by the two TRs in the donor plasmid are inserted into the host genome. 
PiggyBac preferentially integrate into the TTAA sites of the genome (Cary et al., 1989). No 
"footprint" is left in the genome after piggyBac excision. PiggyBac has large cargo capacity and 
can accommodate as much as 14 kb and 18kb of DNA with epiggyBac (Lacoste, et al 2009) 
without compromising transposition efficiency. The number of transposition events can be 
regulated by controlling the concentration of donor and helper plasmids. Overproduction 
inhibition and postintegration silencing has not been reported using piggyBac system yet. It has 
been widely used in insertional mutagenesis, iPS cell induction and lineage tracing studies (Yusa, 
et al 2009; Lu, et al 2009; Rad, et al 2010).  
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Table 3 Comparison of Tol2, Sleeping Beauty and piggyBac transposon 
Transposon Integration site Cargo capacity Footprint Overproducti
on inhibition 
Tol2 random 11kb 8bp no 
Sleeping Beauty TA 12kb 3bp yes 
piggyBac TTAA 18kb no no 
 
Targeted Genome engineering using CRISPR/Cas9 
Genome engineering using homologous recombination (Capecchi, 1989) revolutionized 
biological research. It is capable of providing conclusive causal relationship between genotype 
and phenotype. However, several factors such as the low efficiency of homologous 
recombination, the time consuming and labor intensive strategies hamper its applications. As 
alternative, series of programmable nuclease based genome engineering technologies have been 
developed.  These technologies utilize sequence specific DNA binding domain fused to a 
nonspecific DNA cleavage module (Carroll, 2011; Urnov et al., 2010). These chimeric nucleases 
can introduce double strand break (DSB) at target DNA sites. Efficient and precise genetic 
modifications are then introduced at the DSB sites through DNA repair mechanism including 
error prone non homologous end joining pathway (NHEJ) and homologous directed repair 
pathway (HDR)(Wyman and Kanaar, 2006). Easy production of customized programmable DNA 
binding domains makes this approach versatile and can be used to target virtually any genomic 
location. Four classes of customizable DNA binding proteins: meganucleases(Smith et al., 2006), 
zinc finger proteins (ZFP) (Miller et al., 2007; Urnov et al., 2005), transcription activator like 
effectors (TALEs) (Miller et al., 2011; Moscou and Bogdanove, 2009) and type II clustered 
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regularly interspaced short palindromic repeats (CRISPR) associated endnonuclease Cas9 (Cong 
et al., 2013; Mali et al., 2013) have been engineered to achieve effective genome engineering. 
Due to lack of clear correlation between meganulcease protein residues and their target DNA 
specificity, meganucleases have not been widely used as genome engineering platform (Hsu et 
al., 2014). Compared to CRISPR/Cas9, zinc finger domains and TALE arrays exhibit context-
dependent binding preference (Juillerat et al., 2014; Maeder et al., 2008) and the construction of 
customized DNA binding domain are labor intensive and costly. Unlike meganucleases, ZF and 
TALE proteins recognize DNA sequences through protein-DNA interaction; Cas9 is recruited to 
specific DNA sequences by20 nucleotides short guide RNA (gRNAs). The versatility of CRISPR 
system is greatly facilitated by the easy construction of gRNA. CRISPR system has been become 
a platform technology for targeted genome engineering and modification. 
Endogenous CRISPR/Cas9 system function as bacterial acquired immune system against 
invading foreign DNA such as phage DNA through RNA guided DNA cleavage (Wiedenheft et 
al., 2012). Three types endogenous CRISPR system have been indentified and the type II 
CRISPR system has been engineered for genome editing for its relatively simple structure. Once 
infected, bacteria will convert foreign DNA into short segments (spacers) and incorporate them 
in CRISPR loci. These short spacers will get transcribed and processed into short CRISPR RNA 
(crRNA) via RNase III and Cas9.  The crRNA then hybridize with non coding trans-activating 
crRNAs (tracer RNA) and the crRNA-tracerRNA hybrid then recruit Cas9 to the target site and 
pathogenic foreign DNA is cleaved by Cas9(Gaj et al., 2013). In order for efficient cleavage by 
Cas9, a 3 nucleotide protospacer adjacent motif (PAM) sequence must be present immediately 
downstream the target sites (Jinek et al., 2012). Two pioneer studies in 2013 demonstrated that 
co-delivery of plasmids encoding Cas9, crRNA and tracerRNA successfully modified human 
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genome (Cong et al., 2013; Mali et al., 2013). In only a year, CRISPR/Cas9 system has been 
applied to many applications beyond genome engineering including large scale gene screen 
(Shalem et al., 2014; Wang et al., 2014), activate or repress gene expression (Cheng et al., 2013; 
Gilbert et al., 2013; Qi et al., 2013), visualize specific genomic regions of interest (Chen et al., 
2013), just to name a few. As Rodolphe Barrangou (the scientist who first demonstrated CRISPR 
function as acquired immune system in bacteria) said, "The only limitation today is people’s 
ability to think of creative ways to harness CRISPR"(Pennisi, 2013). 
 
Conclusion 
Despite the fact that we know a lot more about cancer than 50 years ago, we still only know a 
small fraction of it. Cancers still are the leading cause of death and the mortality for cancers 
hasn't changed little in the past 50 years. This is partly because cancer is not a disease; it is 
hundreds if not thousands of diseases. Each different types of cancer might have different cell of 
origin, different genetic mutation or both. New tools thus are badly needed to parse out the 
contribution of cell of origin and genetic mutation to tumor initiation and progression. The ideal 
tools would require convenient tracking of normal development lineage and manipulate the cells 
in the lineage with genomic mutations found in human patients. Transposon and CRISPR/Cas9 
system will complement existing methods for lineage labeling and somatic transgenesis. 
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Chapter 2 A method for stable transgenesis of radial glia lineage in rat neocortex by 
piggyBac mediated transposition 
 
(This chapter is published in Journal of Neurosciecen Methods as Fuyi Chen, Joseph 
LoTurco (2012): A method for stable transgenesis of radial glia lineage in rat neocortex by 
piggyBac mediated transposition. Journal of Neuroscience Methods, 207 (2): 172-180.) 
Abstract 
Methods that combine lineage tracing with cellular transgenesis are needed in order to 
determine mechanisms that specify neural cell types. Currently available methods include viral 
infection and Cre-mediated recombination. In utero electroporation (IUE) has been used in 
multiple species to deliver multiple transgenes simultaneously into neural progenitors. In 
standard IUE, most plasmids remain episomal, are lost during cell division, and so transgenes are 
not expressed in the complete neural lineage. Here we combined IUE with a binary piggyBac 
transposon system (PB-IUE), and show that unlike conventional IUE, a single embryonic 
transfection of neocortical radial glia with a piggyBac transposon system results in stable 
transgene expression in the neural lineage of radial glia: cortical neurons, astrocytes, 
oligodendrocytes, and olfactory bulb interneurons. We also developed a modular toolkit of donor 
and helper plasmids with different promoters that allows for shRNA, bicistronic expression, and 
trangenesis in subsets of progenitors. As a demonstration of the utility of the toolkit we show that 
transgenesis of epidermal growth factor receptor (EGFR) expands the number of astrocytes and 
oligodendrocyrtes generated from progenitors. The relative ease of implementation and 
experimental flexibility should make the piggyBac IUE method a valuable new tool for tracking 
and manipulating neural lineages. 
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Introduction 
In utero electroporation (IUE) is an efficient method for delivering multiple plasmid DNAs 
into CNS progenitors in vivo (Saito and Nakatsuji, 2001; Tabata and Nakajima, 2001).  While an 
effective method for delivering multiple plasmids with high efficiency into the same progenitor, 
it suffers from a disadvantage relative to retrovirus or transgenic reporter lines in that it does not 
result in labeling of an entire lineage. IUE has become widely used in studies of neuronal 
migration in developing neocortex, and is ideal for labeling pyramidal neurons of defined regions 
and layers of neocortex (Bai et al., 2003; Manent et al., 2009).  In order to label a particular cell 
type with IUE, the time and location of transfection is varied based on the birthdate and site of 
generation of that cell type desired to be labeled (LoTurco et al., 2009).  Birthdating by IUE is 
likely caused by plasmid loss and inactivation upon cell division, because viruses applied at the 
same time label an entire lineage that includes neurons and glia (LoTurco et al., 2009).  
A possible non-viral solution to the loss or inactivation of episomal plasmid in IUE is the use 
of DNA transposon systems such as the piggyBac transposon to drive genomic integration of 
transgenes.  Such systems have been used successfully for efficient and stable transgene delivery 
in multiple cell types (Ding et al., 2005; Wilson et al., 2007; Woltjen et al., 2009; Yoshida et al.). 
The typical transposon system involves a transgene from a "donor" plasmid and a "helper" 
plasmid that expresses a transposase. The donor plasmid must contain terminal repeats flanking 
the transgene of interest for transposition into the genome to occur (Cadinanos and Bradley, 
2007). If the helper plasmid does not contain the terminal repeats necessary for DNA 
transposition, then as with any episomal plasmid, expression of the transposase is lost, and 
without further transposase expression transgenes are stably integrated into the genome. 
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    Currently there are two well established transposon systems adapted for use in mammalian 
cells: Sleeping Beauty (SB) and piggyBac (PB) (VandenDriessche et al., 2009). PiggyBac was 
originally isolated from the genome of the cabbage looper moth Trichoplusia ni (Cary et al., 
1989; Elick et al., 1996; Fraser et al., 1995). Compared to Sleeping Beauty, piggyBac has a more 
precise “cut and paste” mechanism (Fraser et al., 1996; Yusa et al., 2009), higher transposition 
efficiency (Wu et al., 2006) and larger cargo capacity (Ding et al., 2005; Lacoste et al., 2009). 
PiggyBac has been used to generate iPS cells (Lacoste et al., 2009; Woltjen et al., 2009; Yusa et 
al., 2009), in gene therapy models (Wilson et al., 2007), and for neuronal development studies in 
Drosophila (Schuldiner et al., 2008) and chicken (Lu et al., 2009).  
Here we report a novel application of piggyBac mediated transgenesis in neocortical 
progenitors in rat by in utero electroporation (PB-IUE). This method, unlike standard IUE, can 
be used to successfully label the complete lineage of neural progenitors: neurons, astrocytes, 
oligodendrocytes and olfactory bulb interneurons. We additionally developed a piggyBac 
plasmid toolkit that allows for shRNA, bicistronic expression and trangenesis in subsets of neural 
progenitors. The relative ease of implementation and inherent flexibility of a plasmid-based 
system should make this method valuable to many interested in marking and manipulating neural 
lineages in the CNS for rats and other species for which Cre reporter lines are not available. 
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Results 
PiggyBac labels cortical lineage of neural progenitors  
We investigated whether piggyBac mediated trangenesis can label the progeny of neural 
progenitors and whether transgenes are stably maintained in progeny. In order to test this, we 
electroporated the piggyBac donor plasmid pPBCAG-eGFP, along with the helper plasmid 
pCAG-PBase, into developing rat brain at embryonic day 13 (E13) or embryonic day 15 (E15), 
using episomal pCAG-mRFP as transfection control (Fig.2-1A). The piggyBac transposon 
system is a binary system with a helper plasmid (pCAG-PBase) providing piggyBac transposase 
(PBase), and the donor plasmid (pPBCAG-eGFP) providing the CAG-eGFP  transgene between 
the 5’ and 3’ terminal repeats (TRs) of the donor plasmid.  
In brains electroporated at E13, RFP labeled neurons were restricted to deep layers while 
GFP labeled cells were found in all layers (Fig. 2-1B). As shown in Fig. 2-1D, deep layer 
neurons were double labeled with GFP and RFP while the upper layer neurons were only 
positive for GFP. GFP positive cells in both grey and white matter were GFAP and S100B 
positive indicating that astrocytes, generated late during cortical development (Kriegstein and 
Alvarez-Buylla, 2009), can also be labeled by piggyBac IUE (Fig. 2-1E-F). When performed 
with pPBCAG-eGFP alone at E13, IUE labeled deep layer neurons but not upper layer neurons 
or astrocytes (data not shown). The absence of upper layer neurons and astrocytes in both 
episomal pCAG-mRFP (Fig. 2-1B) and pPBCAG-eGFP when transfected without the PBase 
expressing plasmid indicates that episomal plasmid is not maintained through multiple 
progenitor cell divisions.  
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   In brains electroporated at E15, at the time when upper layer neurons are generated (Langevin 
et al., 2007), neurons were double labeled with GFP and RFP while astrocytes were only positive 
for GFP (Fig. 2-1C). We also found that there were more astrocytes labeled by E15 
electroporation than by E13 electroporation. At P21, E13 PB-IUE resulted in  79.8 ± 3.3% 
neurons and 20.2 ± 3.3% astrocytes (Fig. 2-1G), while at E15 there were 26.6 ± 2.7% neurons, 
73.4 ± 2.7% astrocytes ( one way ANOVA, p<0.0001). In summary, unlike conventional IUE 
with episomal plasmid which only labels birthdated progeny, single embryonic transfections with 
the piggyBac system results in labeling of all cell types in the lineage of embryonic neocortical 
progenitor cells. 
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Figure 2-1 PiggyBac labels radial glia lineages 
 
(A), Schematic representation of plasmids used. (B), Images of brains electroporated at E13. (C), 
Image of brains electroporated at E15. (D), Upper layer neurons were labeled with GFP but not 
RFP. Deep layer neurons were double labeled with GFP and RFP. (E), GFP labeled cells that 
were positive for S100B in both white matter and gray matter. (F), GFP labeled cells that were 
GFAP positive in both white matter and gray matter. (G), Quantifications of astrocyte to neuron 
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ratio in brains electroporated at E13 and E15. Asterisk indicates significant difference (one way 
ANOVA, P< 0.001). Scale bar: 200 µm in B, 50 µm in C, 20 µm in D and E, 500 µm in F. 
PiggyBac labels olfactory bulb interneurons and oligodendrocytes 
To further demonstrate lineage labeling of neural progenitors by the piggyBac system, we 
assessed the presence of other cell types not typically labeled by standard IUE. We found GFP+ 
but RFP- labeled granule cells and periglomerular cells in the olfactory bulb (Fig. 2-2A). GFP 
positive cells were positive for the neuroblast marker DCX and these cells were found in rostral 
migratory stream (RMS) (Fig. 2-2B). In the SVZ of P21 brains, we found GFP positive cells 
positive for both GFAP (Fig. 2-2C) and Ki67 (Fig. 2-2D). Taken together, these results show that 
piggyBac IUE applied embryonically labels stable staining of SVZ neuroblasts, migrating RMS 
cells, and olfactory bulb interneurons. 
The next question we asked was whether piggyBac IUE could label oligodendrocytes. GFP 
positive cells showed oligodendrocyte (Fig. 2-2F) morphology and were positive for the 
oligogendrocyte marker CC1 in both grey matter and white matter. Cells co-expressing GFP and 
the oligodendrocyte precursor marker NG2 were also found in both white and grey matter (Fig.2- 
2E), supporting the hypothesis that radial glia are a source of at least some oligodendrocyte 
precursors (Malatesta et al., 2003; Trotter et al., ; Ventura and Goldman, 2007).  
  Next we applied piggyBac IUE in hippocampus. When we electroporated hippocampus at E15 
with the piggyBac donor (pPBCAG-eGFP) and helper (pCAG-PBase) plasmids, GFP positive 
cells were found in CA1, CA2, CA3 and dentate gyrus. As shown in Fig. 2-2G, GFP positive 
neurons, astrocytes (GFAP positive), oligodendrocytes (CC1 positive) and oliogodendrocyte 
precursors (NG2 positive) were present in hippocampus. In contrast, in brains electroporated 
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with pPBCAG-eGFP alone, without the PBases expression plasmid, neurons but not astrocytes 
or oligodendroyctes were labeled by GFP (data not shown). Taken together, our data show that 
piggyBac IUE can be used to label the lineage of progenitors present at the surface of the 
ventricular zone in the neocortex, olfactory bulb and hippocampus. 
Figure 2-2 PiggyBac labels olfactory interneurons and oligodendrocytes 
 
(A), Left panel, Image of P21 olfactory bulb stained with DAPI. GFP positive cells can be seen. 
Right panel, confocal image of GFP labeled cells in glomeruli. (B), Confocal images of DCX 
positive cells labeled with GFP in RMS. (C), GFAP positive cells in SVZ double labeled for 
GFP. (D), Ki67 positive cells in SVZ positive for GFP. (E), NG2 positive cells labeled with GFP 
in white matter. (F), CC1 positive cells labeled with GFP in white matter. (G), Left, images of 
hippocampus electroporated at E15. Right, GFAP positive, CC1 positive, and NG2 positive cells 
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labeled with GFP in hippocampus. Scale bar: A: 100 µm in left panel and 10 µm in right panel. 
20 µm in B- G: 50 µm in left panel and 20 µm in right panel. 
 
A modular plasmid toolkit for piggyBac IUE  
 The inherent experimental flexibility of a plasmid system led us to develop additional 
plasmids that can be used in combination for gain- and loss- of function studies.  In addition, we 
developed plasmids with different promoters in order to selectively target progenitors and 
progeny of different types (Fig. 2-3).  First, we produced an shRNA piggyBac donor plasmid 
(pPBmU6pro) which contains the U6 promoter to drive expression of shRNAs for RNAi 
experiments. Second, we made and tested a bicistronic eGFP-t2a-mRFP donor plasmid 
(pPBCAG-eGFPt2amRFP).  This T2A donor plasmid can be used to express two proteins from 
the same transcript, and so by replacing the mRFP cassette with a gene of interest this plasmid 
can be useful in experiments where a "within tissue" control is desirable.  For example, clones in 
which eGFP signal is present (i.e. containing the transgene for a gene of interest) can be 
compared to clones that are missing an eGFP signal but labeled by other fluorescent proteins. 
Finally, the binary nature of the piggyBac system makes possible independent control of the 
promoters in helper and donor plasmids.  We have made a series of helper and donor plasmids 
with different promoters that can be used alone or in combination. These include the helper 
plasmids pGLAST-PBase, pGFAP-PBase, pTα1-PBase and pNestin-PBase and donor plasmids 
pPBGFAP-eGFP, pPBDCX-eGFP, pPBMBP-eGFP and pPBCAMKII-eGFP.  Conceptually, 
these can be mixed in different combinations of donor and helper to integrate transgenes in 
subpopulations of progenitors (selected by the promoter in the helper plasmid), and have the 
transgene expressed in subsets of progeny (selected by the promoter in the donor plasmid).  For 
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example, by combining pGLAST-PBase with pPBGFAP-eGFP it is possible to label the 
astrocytes generated from GLAST positive progenitors.  
Figure 2-3 PiggyBac toolkit 
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(A), Schematic summaries of piggyBac helper plasmids with five different promoters available 
to drive expression of PBase. (B), Schematics of the collection of piggyBac donor plasmids, 
including multi color piggyBac donor plasmid, donor plasmid driven by cell type specific 
promoters, bicistronic donor plasmid and donor plasmid for expression of shRNAs by the U6 
promoter. 
EGFR transgenesis expands astrocyte clones in cortex 
 To demonstrate the utility of the multi plasmid piggyBac system in gain-of-function 
experiments, we transfected a piggyBac system mixture of plasmids containing fluorescent 
proteins. Transfection of three fluorescent trangenes (pPBCAG-eGFP, pPBCAG-mRFP and 
pPBCAG-CFP) resulted in approximately 70% of cells expressing all three fluorescent proteins, 
albeit at varied levels, 20% expressing 2 and 10% expressing one fluorescent protein. This 
relatively high co-expression rate indicated that gain-of-function experiments could be achieved 
in combination with two-color labeling by simply adding additional donor plasmids to the 
transfection mixture. For these IUE experiments we used the GLAST promoter to direct 
expression of transposase in radial glia at E15. In a test of this gain-of-function application we 
introduced a donor plasmid, pPBCAG-EGFR, which encodes epidermal growth factor receptor 
(EGFR).  EGFR expression has been previously shown to increase the proliferation of astrocyte 
progenitors, and we hypothesized that increased proliferation of astrocytes or astrocyte 
progenitors would result in more cells in same color astrocyte groups. As shown in Fig.2-4 A-D 
the expression of EGFR increased the density of astrocytes in cortex and striatum. Within 
neocortex, EGFR trangenesis expanded same color astrocyte groups and this gave rise to large 
patches of single color groupings of astrocytes. This expansion was further demonstrated by a 
significant increase in the distribution of distances between same color cells within 250 x 250 
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µm regions (Fig. 2-4E). The EGFR related expansion of same color distances is consistent with 
previous studies showing an increase in proliferation of astrocytes following EGFR 
overexpression (Ayuso-Sacido et al., ; Burrows et al., 1997; Sun et al., 2005), and extends these 
results to show that clonal expansion can result in an increase in the spatial domains occupied by 
clonally related astrocytes. Moreover, the result supports the idea that same color groups of 
astrocytes are clonally related and demonstrates the gain-of-function application. 
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Figure 2-4 EGFR transgenesis induces spatial expansion of same colored astrocyte groups 
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(A), Images from a control transfected hemisphere at P27 transfected with the multicolor plasmid 
system without the addition of an EGFR donor plasmid. (B), Example of a hemisphere at P27 
transfected with EGFR donor plasmid and the multicolor plasmid system. High magnification of 
control transfected cortex is shown in (C) and EGFR transfected cortex is shown in (D). (E), 
Cumulative probability histogram showing the distribution of same colored cell distances in 
plasmid. (Kolmogorov-Smirnov; P<0.0001). Scale bar: 500 µm in A and B, 100 µm in C and D. 
Patterned clonal astrocyte expansion following EGFR transgenesis 
 In areas outside of dorsal-lateral neocortex, EGFR transgenesis showed unique patterns 
of multicolor labeling that were not apparent in transfections without EGFR. Large color-defined 
patches of astrocytes appeared following EGFR transgenesis (Fig. 2-5A) in the forebrain medial 
wall and the striatum. Without EGFR transgenesis only scattered cells in striatum were labeled 
(Fig. 2-4A), but as shown in Fig.2-4B and Fig.2-5B, after EGFR transgenesis extremely large 
single color groups of astrocytes were found spread throughout striatum. EGFR trangenesis also 
expanded oligodendrocytes of single color within the anterior commissure and corpus callosum 
(data not shown). The number of interneurons labeled in the olfactory bulb was also increased 
following EGFR transgenesis. Unlike astrocytes, granule cell numbers in the olfactory bulb were 
expanded without any apparent clustering of color-defined groups suggesting that expansion of 
granule cell numbers did not result in expansion of spatially restricted clonal related neurons (Fig. 
2-5C). Astrocytes in the olfactory bulb, similar to astrocytes elsewhere, showed expansion of 
single color groups (Fig. 2-5D). 
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Figure 2-5 EGFR induced patterns of clonal expansion in forebrain 
 
(A), Image of an anterior section from a P27 rat brain with EGFR trangenesis. Large astrocyte 
groupings were observed as shown in A1. Stripes of astrocytes of same color are also noticeable. 
(B), Striatum with EGFR transgenesis. Large same color astrocyte groupings were apparent with 
some color mixing within the larger groups. B1 shows an example of large red astrocyte 
grouping mixing with other astrocytes. (C), Images of olfactory bulb with EGFR transgenesis. 
Expansion of the number of olfactory interneurons and clonal mixing were observed. Higher 
magnification of the olfactory ventricle, granule layer and periglomerular layer are shown in C1, 
C2 and C3. (D), Images of olfactory bulb with same color astrocyte clusters in the EGFR 
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transgenesis condition. Examples of astocytes in olfactory bulb are shown in D1 and D2. Scale 
bar: 100 µm in A-D, 20 µm in A1, B1, C1, C2 and C3, 50 µm in D1 and D2. 
 
Discussion 
In utero electroporation (IUE) is a relatively efficient method for delivering plasmid DNA into 
CNS progenitors in vivo (Saito and Nakatsuji, 2001; Tabata and Nakajima, 2001). The approach 
has become widely used in studies of neuronal migration in developing neocortex, and is ideal 
for labeling pyramidal neurons of defined regions and layers of neocortex (Bai et al., 2003; 
Manent et al., 2009). While an effective method, it suffered from a disadvantage, relative to 
retrovirus, when applied to neocortex in that it did not reliably label the entire lineage of radial 
glia. Here we reported that the combination of in utero electroporation and piggyBac mediated 
transposition (PB-IUE) successfully labels the lineage of radial glia. The method extends the 
application of IUE to a unique lineage labeling approach in which the "birthdated" progenies are 
labeled by two transgenes and subsequent progenies are labeled only by transgenes flanked by 
terminal repeats (Fig. 1). The utility of this type of lineage labeling is in being able to express 
one transgene in only the birthdated progeny (first member of a lineage near the time of 
transfection) but not in the subsequent progeny of the lineage. We also demonstrated that the 
piggyBac system can be readily adapted to gain-of-function applications. The modular plasmid 
toolkit can be used to create RNAi, bicistronic expression, and/or selected transgene integration 
into defined progenitors and progeny. The relative ease of implementation, and inherent 
flexibility of a plasmid-based system, should make this method and toolkit valuable to many 
interested in marking and manipulating neural lineages in the CNS. 
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Any method taking advantage of multiple random genomic integration events raises the risk 
of insertional mutagenesis altering results. In fact, insertional mutagenesis by transposases has 
been used for identification of cancer related genes in engineered mouse lines (Collier et al., 
2005; Starr et al., 2009). These systems of mutagenesis however require constant expression of 
the transposase to allow for multiple transposition events, and the system we used results in 
piggyBac transposase expression that is limited to immediate progeny and not propagated into 
dividing members of the lineage. Moreover, we did not observe evidence of mutagenesis based 
on inspection of morphologies of thousands of neurons and even more astrocytes labeled with 
the piggyBac IUE method.  
  In conclusion, piggyBac mediated transgenesis approach will complement existing methods 
for the study of neural lineages and glial cells in brain development. The piggyBac toolkit shall 
be proven powerful in radial glia lineage labeling and manipulation. 
Methods 
Plasmids 
Both the 3’ and 5’ piggyBac terminal repeats (3’TR and 5’TR) were amplified from pZGs 
(Wu et al., 2007). To make pPBCAG-eGFP, the 3’TR was cloned into pCAG-eGFP (Matsuda 
and Cepko, 2007) using SalI and SpeI sites and the 5’TR was cloned into the same vector using 
PstI and HindIII sites. For construction of pPBCAG-mRFP, the eGFP cassette in pPBCAG-
eGFP was replaced by mRFP cassette from pCAGGS-mRFP (Manent et al., 2009) using XbaI 
and BglII. pCAG-PBase was constructed by replacing eGFP with PBase  sequence (Wu et al., 
2007) in pCAG-eGFP using EcoRI and NotI sites. pGLAST-PBase was made by inserting PBase 
downstream of GLAST promoter provided by Dr. DJ Volsky (Kim et al., 2003). To make 
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pPBCAG-EGFR, human wild type EGFR was PCR amplified from EGFR WT (Greulich et al., 
2005) (Addgene plasmid 11011), and inserted into KpnI and NotI sites of pPBCAG-eGFP. 
 
Construction of a piggyBac Toolkit 
 
To make pPBCAG-CFP, CFP sequence was amplified from CMV-Brainbow-1.0 (Livet et al., 
2007), (Addgene plasmid 18721) and replaced the eGFP cassette in pPBCAG -eGFP using 
EcoRI and NotI sites. For construction of pNestin-PBase, pGFAP-PBase and pTalpha1-PBase, 
PBase coding sequence was directly inserted downstream of the rat Nestin promoter, a gift from 
Dr. Steven Goldman (Roy et al., 2000), mouse GFAP promoter, a gift from Dr. Vijay Sarthy 
(Kuzmanovic et al., 2003) and Talpha1 promoter, a gift from Dr. Albert Ayoub and Dr. Pasko 
Rakic (Gal et al., 2006), respectively. For construction of pPBGFAP-eGFP, pPBDCX-eGFP, 
pPBCamKII-eGFP and pPBMBP-eGFP, CAG promoter in pPBCAG-eGFP was replaced with 
mouse GFAP promoter provided by Dr. Vijay Sarthy (Kuzmanovic et al., 2003), mouse DCX 
promoter, a gift from Dr. Qiang Lu (Wang et al., 2007), rat MBP promoter, a gift from Dr. Robin 
Miskimins (Wei et al., 2003), and CamKII promoter  (Chow et al.), (Addgene plasmid 22217), 
respectively. For construction of bicistronic donor plasmid pPBCAG-eGFPt2amRFP, T2A 
sequence gagggcaggg  gaagtctact aacatgcggg gacgtggagg aaaatcccgg ccca was added to the 3’ 
end of eGFP coding sequence using standard PCR method and then eGFP T2A was inserted into 
the XbaI/EcoRI sites of pPBCAG-mRFP. For future cloning into the T2A plasmid, EcoRI/ BglII 
sites can be used to replace mRFP with gene of interest. Construction of  pPB-mU6pro was 
achieved by inserting piggyBac terminal repeats into the mU6pro vector (Yu et al., 2002). 3’TR 
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was inserted into the Not1 site and 5’TR was inserted into the PstI/HindIII sites of mU6pro. 
shRNA sequence can be cloned into the XbaI/BbsI sites. 
Animals 
Pregnant Wistar rats were obtained from Charles River Laboratories, Inc. (Wilmington, MA) 
and maintained at the University of Connecticut vivarium. Animal gestational ages were 
determined and confirmed during surgery. Both male and female embryos were used. All 
procedures and experimental approaches were approved by the University of Connecticut 
IACUC. 
In utero electroporation 
In utero electroporation was performed as previously described (Bai et al., 2003; Ramos et 
al., 2006). Briefly, rats were anesthetized with a mixture of ketamine/xylazine (100 / 10 mg/kg 
i.p.). Metacam analgesic was administered daily at dosage of 1 mg/kg s.c. for 2 days following 
surgery. To visualize the plasmid during electroporation, plasmids were mixed with 2mg/ml Fast 
Green (Sigma). In all conditions, pPBCAG-eGFP, pPBCAG-mRFP, pPBCAG-EGFR, pCAG-
eGFP and pCAG-mRFP were used at the final concentration of 1.0 μg/μl, while pCAG-PBase 
and pGLAST-PBase were used at the final concentration of 2.0 μg/μl. Electroporation was 
performed at embryonic day 13 or 15 (E13 or E15). During surgery, the uterine horns were 
exposed and one lateral ventricle of each embryo was pressure injected with 1-2 μl of plasmid 
DNA. Injections were made through the uterine wall and embryonic membranes by inserting a 
pulled glass microelectrodes (Drummond Scientific) into the lateral ventricle and injecting by 
pressure pulses delivered with a Picospritzer II (General Valve). Electroporation was 
accomplished with a BTX 8300 pulse generator (BTX Harvard Apparatus) and BTX 
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tweezertrodes. A voltage of 65-75v was used for electroporation. Hippocampal electroporation 
was performed as previously described (Navarro-Quiroga et al., 2007). 
Immunohistochemistry 
Animals were deeply anesthetized with isoflurane and perfused transcardially with 4% 
paraformaldehyde/PBS (4% PFA). Brain samples were post fixed overnight in 4% PFA and 
sectioned at 65 µm thickness on vibratome (Leica VT 1000S). Sections were processed as free-
floating sections. After blocking in PBS containing 5% of normal goat serum (Sigma,) and 0.3% 
Triton X-100 (Sigma) for 1h at room temperature, tissue sections were incubated with primary 
antibodies overnight at 4°C in the blocking solution. The following primary antibodies were used: 
mouse anti-GFP (1:1000, Molecular Probes), rat anti-DsRed (1:1000, Molecular Probes), rabbit 
anti-Ki67 (1:1000, Novus Biologicals ),mouse anti-GFAP (1:200, Chemicon) , mouse anti NG2 
(1:500, Chemicon), mouse anti-CC1(1:200, Santa Cruz).Tissue sections were washed in PBS, 
incubated with the appropriate secondary antibodies (all Alexa Fluor in 1: 200, Invitrogen,)  for 
2hs at room temperature (Alexa Fluor 488 anti-mouse IgG, Alexa Fluor 488 anti-rabbit IgG, 
Alexa Fluor 568 anti-mouse IgG, Alexa Fluor 568 anti-rabbit IgG, Alexa Fluor 647 anti-rabbit 
IgG, Invitrogen) and washed in PBS. In some tissues, nuclei were labeled with TOPRO-3 
(Molecular Probes) and 4-6-diaminodino-2-phenylindole (DAPI, Invitrogen).  Images were 
acquired on either a Leica TCS SP2 confocal system or Stereo Investigator (Microbright Field) 
with the HAMAMATSU digital camera C10600. Montage images were taken using the virtual 
slice function of Stereo Investigator (Microbright Field). 
Neighbor analysis and statistics 
For neighbor analysis virtual slices were taken using Stereo Investigator (Microbright Field). 
The virtual slices were divided into 250 × 250 μm grids. Distances between cells with the same 
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color were measured within the grid and was analyzed by Neurolucida Explorer (Microbright 
Field). Neighbor analysis was performed both in control conditions and EGFR over expression 
conditions. To statistically compare changes in the distance distributions in control condition and 
EGFR over expression condition determined by neighbor analysis, the Kolmogorov-Smirnov test 
was performed (http://www.physics. csbsju.edu/stats/ KS-test.n.plot_form.html).  To compare 
ratios of labeled cells that were astrocytes or neurons, a one-way analysis of variance (ANOVA) 
was performed by KaleidaGraph version 4.0 (Synergy Software 2006). A confidence interval of 
95% (p < 0.05) was required for values to be considered statistically significant. All data are 
presented as standard error of the mean (SEM).  
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Chapter 3 Contribution of Tumor Heterogeneity in a New Animal Model of CNS Tumors 
 
(This chapter is published in Molecular Cancer Research as: Fuyi Chen, Albert Becker and 
Joseph J. LoTurco (2014): Contribution of Tumor Heterogeneity in a New Animal Model of 
CNS Tumors. Molecular Cancer Research; doi:10.1158/1541-7786.MCR-13-0531) 
Abstract 
The etiology of central nervous system (CNS) tumor heterogeneity is unclear. To clarify this 
issue, a novel animal model was developed of glioma and atypical teratoid/rhabdoid-like tumor 
(ATRT) produced in rats by non-viral cellular transgenesis initiated in utero. This model system 
affords the opportunity for directed oncogene expression, clonal labeling, and addition of tumor-
modifying transgenes. By directing HRasV12 and AKT transgene expression in different cell 
populations with promoters that are active ubiquitously (CAG promoter), astrocyte-selective 
(GFAP promoter), or oligodendrocyte-selective (MBP promoter); thus, generating glioblastoma 
multiforme (GBM) and anaplastic oligoastrocytoma (AO), respectively. Importantly, the GBM 
and AO tumors were distinguishable at both the cellular and molecular level. Furthermore, 
proneural basic-helix-loop-helix (bHLH) transcription factors, Ngn2 (NEUROG2) or NeuroD1, 
were expressed along with HRasV12 and AKT in neocortical radial glia, leading to the formation 
of highly lethal atypical teratoid/rhabdoid-like tumors (ATRT). This study establishes a unique 
model in which determinants of CNS tumor diversity can be parsed out and reveals that both 
mutation and expression of neurogenic bHLH transcription factors contributes to CNS tumor 
diversity.   
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Introduction 
Tumors of the central nervous system (CNS) have significant intra- and inter-tumor 
heterogeneity in terms of cellular composition, cellular proliferation, invasiveness and epigenetic 
status (Sturm et al., 2012; Verhaak et al., 2010). Integrative large scale gene expression analysis 
of 200 GBM tumors revealed 4 subtypes: proneural, neural, classical and mesenchymal (Verhaak 
et al.).  A more recent GBM classification based on a combination of epigenetics, copy number 
variation, gene expression and genetic mutations has lead to identification of as many as six 
GBM subgroups (Sturm et al., 2012). In addition, there are at least two prognostic subgroups of 
pediatric GBM based on association with or without aberrantly active Ras/AKT pathway (Faury 
et al., 2007; Haque et al., 2007). Heterogeneity in GBM tumors may be responsible for 
differential response to therapeutic interventions (Verhaak et al., 2010), and understanding the 
etiology of tumor heterogeneity in animal models may become increasingly important to design 
therapeutic strategies effective at targeting molecularly defined tumor subtypes.  
Several animal models of brain tumor, including xenograft models, genetically engineered 
mouse models (GEMs) and models utilizing virus-mediated somatic cell transgenesis have been 
used to address important aspects of CNS tumor biology. For example, GEMs harboring 
mutations found in human gliomas have been used to assess tumorigenic effects of individual 
genes and mutations and to reveal the tumor cell-of-origin in some models (Liu et al., 2011; 
Persson et al., 2010). Endogenous cell populations have been induced to form gliomas by both 
viral and non-viral somatic transgenesis of oncogenes or deletion of tumor suppressor genes in 
specific target cell populations (Alcantara Llaguno et al., 2009; Friedmann-Morvinski et al.; 
Hambardzumyan et al., 2009; Holland et al., 2000; Holland et al., 1998; Holmen and Williams, 
2005; Lindberg et al., 2009; Marumoto et al., 2009; Uhrbom et al., 2002; Uhrbom et al., 1998; 
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Wiesner et al., 2009).  For example, oligodendrocyte precursor cells (OPCs) can be the cell-of-
origin for adult glioma (Lindberg et al., 2009; Liu et al., 2011; Persson et al., 2010) with OPC 
originated glioma matching the human proneural subgroup of GBM (Lei et al., 2011; Liu et al., 
2011). Friedmann-Morvinski et al. found that RNAi knock-down of NF1 and p53 expression in 
either astrocytes (GFAP+) or neurons (SynI+) induced formation of mesenchymal GBM 
subtypes, while the same RNAi in Nestin positive neural progenitors induced neural GBM 
subtypes (Friedmann-Morvinski et al., 2012). To more fully explore causes of tumor diversity in 
cerebral cortex we have developed an animal model in which multiple transgenes can be 
expressed in selected cell populations at different times in forebrain development.   
DNA transposon systems have been previously adapted to non-viral somatic transgenesis in 
studies of neocortical development (Chen and LoTurco, 2012; Siddiqi et al., 2014), cellular 
reprogramming (Yusa et al., 2009), and to generate animal models of glioma (Wiesner et al., 
2009). In utero electroporation is a relatively efficient method to deliver multiple combinations 
of transgenes into neuronal and glial progenitors in the developing forebrain in utero (LoTurco et 
al., 2009).  When combined with a DNA transposon system including cell-type specific 
promoters, it becomes possible to introduce multiple transgenes, including oncogenes, in 
different populations of cells (Chen and LoTurco, 2012; Lu et al., 2009; Siddiqi et al., 2014; 
Yoshida et al., 2010). Active Ras pathway(Guha et al., 1997) and PI3K-AKT pathway(Holland 
et al., 2000; Ramaswamy et al., 1999) have been frequently found in human glioma patients and 
used in various glioma animal models (Holland et al., 2000; Holmen and Williams, 2005; 
Marumoto et al., 2009; Uhrbom et al., 2002). In the model described here, we introduced 
HRasV12 and AKT in cell populations in the radial glia lineage to ask whether diversity in 
glioma is linked to the population of cells induced to express oncogenic transgenes.  We also 
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tested whether addition of neurogenic transcription factors to the starting progenitor population 
modifies tumor type.  We show by several measures including morbidity, histology, 
developmental time course, tumor clonal pattern and molecular signature, that diverse tumors are 
generated when oncogene expression is directed into different cell populations.  Moreover, 
expression of the basic helix-loop-helix transcription factors Ngn2 or NeuroD1 along with 
HRasV12 and AKT results in atypical teratoid rhabdoid tumor like tumors (ATRT-like), a 
pediatric tumor type rarely produced in existing tumor models.  
 
 
Results 
A model of GBM by piggyBac-mediated somatic transgenesis  
We developed a non-viral somatic cell transgenesis approach to produce tumors from 
endogenous rat neural progenitors in vivo. HRasV12 and AKT transgenes were introduced into 
embryonic neocortical neural progenitors, also known as radial glial progenitors, by in utero 
electroporation of the lateral ventricles of embryonic rats. For non-viral cellular transgenesis we 
produced a system of plasmids consisting of a helper plasmid that expresses the piggyBac 
transposase in radial glial progenitors via the GLAST promoter (GLAST-PBase) and thereby 
drives transposon integration into the genomes of radial glia progenitors, and a set of donor 
plasmids containing transgenes flanked by transposon inverted terminal repeats (ITRs) to be 
integrated into the genome by piggyBac transposase activity. The donor plasmids included 
HRasV12 and AKT under the control of one of three different promoters (CAG, MBP or GFAP), 
(Figure 3-1A) and a multicolor system of donor plasmids (Siddiqi et al.) with the CAG promoter 
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driving expression of eGFP, mRFP or CFP to create multicolor clonal labeling (Fig 3-1A) 
(Siddiqi et al.; Weber et al.). Electroporation of this system of plasmids unilaterally into the 
lateral cerebral ventricles of E14-E15 rat embryos (Fig 3-1A) invariably resulted by twenty one 
days after birth in the formation of large unilateral tumors (Figure 3-2F). Tumors were composed 
of both regions of uniformly colored cells indicating significant regionalized clonal expansion 
(Fig. 3-1 C and D), and regions containing a mixture of differently colored cells indicating clonal 
mixing (Fig. 3-1F). In addition to tumors, streams of cells typically of one or 2 different colors 
were found distal to the tumor core.  These streams were frequently in directionally oriented 
chains suggesting migration and invasion into surrounding neural tissue (Fig. 3-1E). Survival 
experiments showed that tumor bearing animals began dying at 3 weeks of age and the rate of 
death appeared stable by 31 weeks after birth for the CAG donor plasmid treated animals (Fig. 3-
2E). Tumors were confirmed in all electroporated animals (30/30). 
Histologically, tumors induced by HRasV12 and AKT driven by the CAG donor plasmids 
were composed of fibrillary and gemistocytic elements (Supplementary Figure 1A). The tumors 
diffusely infiltrated neighboring tissues (Supplementary Figure 1B) and had cells with highly 
pleomorphic cytological appearance, and increased mitotic activity indicative of malignancy 
(Supplementary Figures 1C). Tumor cells frequently invaded the subarachnoidal space (Fig.3- 
2G), and tumors had areas of necrosis indicative of high malignancy (Fig 3-2H arrow). Tumors 
appeared by P7 and necrotic areas were found as early as at P4. Immunohistochemical analysis 
revealed that tumor cells showed strong positivity for GFAP (Figure 3-2I), Vimentin (Figure 3-2 
J) and MAP2 (Figure 3-2K). Some neurons entrapped within tumors were positive for 
synaptophysin, while the bulk of the tumors did not show synaptophysin positivity. Interestingly, 
we did not observe vascular proliferation in the rat tumors produced by the CAG donor plasmids 
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but observed vascular proliferation in tumors induced by all other plasmid combinations used in 
this study. Moreover when cultured in neurosphere suspension medium, tumor cells can form 
tumor spheres (Supplementary Figure 2).  In sum, the piggyBac transposon system effectively 
produces a tumor model resembling human GBM (WHO Grade IV).  
Figure 3-1 Multicolor rat glioma 
 
(A) Schematic representation of piggyBac IUE approach and plasmids used.  In utero 
electroporation was performed between E14-E15 with plasmids listed. We used the multicolor 
piggyBac system to clonally label cells, oncogene donor plasmids to induce tumors and both 
donor and conventional epsiomal plasmids encoding transcription factors to evaluate their role in 
gliomagenesis. After the animals were born, tumor assessment was performed at different 
postnatal ages. (B) Representative images of a P22 rat brain hemisphere transfected with 
multicolor piggyBac plasmids and PBCAG-HRasV12/ATK donor plasmids. Necrosis is labeled 
with N. (C) Overlay image showing large regions of tumor cells were uniformly labeled with 
mRFP. (D) Overlay image showing other regions of tumor were uniformly labeled with eGFP.  
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(E) Streams of tumor cells invading tissue adjacent to tumors.  (F) Region of the tumor 
containing a mixture of red and green labeled tansformed cells indicating regions of clonal 
mixing.  (G) 3D reconstruction of 5 tumor clones in a P27 rat transfected with PBGFAP-
HRasV12/AKT. CT, cortex. CC, corpus callosum.  Scale bar: 500 µm in B and 100 µm in C, D, 
E and F. 
 
MBP and GFAP promoter directed oncogene expression produces distinct tumor types  
The binary piggyBac system allows for directing insertion of transgenes in one population of 
cells (i.e. radial glia neural progenitors), but then delayed expression of oncogene expression in 
later generated cell types in the lineage.  This feature allowed us to introduce oncogenes into 
neural progenitors at the embryonic lateral ventricle surfaces, but then have their expression 
turned on later, primarily in either astrocytes, or oligodendrocytes. For this experiment, we 
constructed donor plasmids in which HRasV12 and AKT expression was controlled by either a 
mouse GFAP promoter fragment (Chen and LoTurco, 2012) (PBGFAP-HRasV12/AKT) or a rat 
MBP promoter fragment (Wei et al., 2003) (PBMBP-HRasV12/AKT). We first assessed the 
activity of the mouse GFAP and rat MBP promoters using GFP as a reporter. We found that the 
GFAP promoter resulted in 69.3±3% astrocytes, 19.4±2% neurons, 7.1±2% oligodendrocytes 
and 4.3±0.7% oligodendrocyte precursor cells. In contrast, the MPB promoter construct 
(PBMBP-eGFP/mRFP) labeled 57.0±2% oligodendrocytes, 16.2±0.7% astrocytes, 19.3±2% 
neurons, and 7.5±0.7% oligodendrocyte precursor cells (Figure 3-2C and D). One way ANOVA 
showed a significant difference between GFAP and MBP promoter labeled astrocytes (p= 6.91E-
05) and oliogodendrocytes (p=2.69E-05). A significant difference was also found between NG2 
cells labeled by GFAP and MBP promoters (One-way ANOVA, p=0.021172), but no significant 
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difference was found between the fraction of labeled neurons (One-way ANOVA, p=0.989884). 
The differences in the cell populations labeled by the MBP and GFAP promoter fragments is 
consistent with enriched targeting of oligodendrocytes and astrocytes respectively; however, 
each promoter was also capable of labeling some fraction of each cell type.  
 We next compared and contrasted tumors produced by the donor plasmids containing either 
the GFAP or MBP promoters driving oncogene expression.  For both donor plasmids, tumors 
resulted in all animals and death resulted in 65.2% (15/23) of animals by 40 weeks (Figure 3-2 E 
and F).  A log rank test showed no significant difference in survival among animals bearing 
tumors induced by GFAP, MBP or CAG donor plasmids (Log rank test, p=0.194 between CAG 
and GFAPP, p=0.554 between GFAP and MBP donor plasmids transfected animals. For 
comparison between CAG and MBP donor plasmids transfected animals, Log rank test p=0.093, 
Breslow test p=0.121, Tarone-Ware test p=0.106). A histopathological analysis of tumors in both 
GFAP and MBP promoter conditions indicated frequent mitotic figures (Supplementary Figure 
1D, Fig. 3-2R, black arrow), similar to the CAG promoter condition described above, but also 
showed vascular proliferates consistent with highly malignant tumor types.  Tumors were 
observed in 23 out of 23 animals assessed for tumors 14 days to 280 days after birth. In addition, 
GFAP donor plasmid induced tumors, unlike the MBP plasmids, resulted in tumors with 
prominent necrotic foci frequently surrounded by “pseudopalisading” tumor cells (Figure 3-2M 
arrow). Immunohistological assessment of tumors induced by GFAP donor plasmids indicated 
process rich astroglial cells with delicate processes positive for GFAP, Vimentin and MAP2 
(Figure 3-2N-P). We conclude based on the histopathological findings that the GFAP donor 
plasmid induced tumors are malignant astroglial tumors resembling human GBM (WHO Grade 
IV). While similar in many ways to tumors induced by the CAG donor plasmid the multicolor 
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clonal analysis indicated that the GFAP donor plasmids resulted in tumors with larger clonal 
territories than the CAG donor plasmids.  Similarly, the tumors in the GFAP donor plasmid 
condition showed more clonally associated invasion and expansion into striatum than did tumors 
in the CAG donor plasmid condition. 
 In contrast to the GFAP and CAG donor plasmid induced tumors, the MBP donor 
plasmids induced tumors contained a mixture of astroglial and oligogdendroglial components, 
and lacked prominent necrotic foci and pseudopalisading cell arrangements typical of the GFAP 
donor plasmids induced tumors (Figure 3-2M). In some areas of MBP donor plasmid induced 
tumors there were processes with GFAP and Vimentin positivity (Figure. 3-2S and T), but these 
areas were less frequently observed than in the GFAP donor plasmid induced tumors. In addition 
to the small astroglial cell fraction, the MBP donor plasmid induced tumors contained prominent 
‘honeycomb’-like cell clusters (Figure 3-2Q) with round isomorphic nuclei located centrally to 
perinuclear halos (Figure 3-2R inset): a feature resembling cytological characteristics of human 
oligodendroglioma.  Cells were largely negative for Vimentin (Fig. 3-2T), but positive for MAP2, 
an immunostaining pattern consistent with mixed oligodendroglial and astroglial components.  
MAP2 immunopositivity showed strong perinuclear cytoplasmic staining without significant 
process labeling (Figure 3-2U black arrow, inset) typical of oligodendroglioma.  Some MAP2 
stained cells in MBP donor plasmid induced tumors displayed bi- or multi-polar processes 
typical of astroglial cells (Figure 3-2U grey arrow). In sum, the histological and 
immunohistochemical patterns observed in the tumors induced by MBP donor plasmids were 
distinct from those observed with the GFAP and CAG donor plasmids, and are most similar to 
human anaplastic oligoastrocytoma (WHO Grade III).  
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Figure 3-2 Distinct tumor types are induced by different donor plasmids 
 
(A)Mouse GFAP promoter fragment labeled astrocytes. (B) Rat MBP promoter fragment labeled 
oligodendrocytes. 
(C) Quantification of proportions of labeled cells by GFAP and MBP promoter fragments (One 
way ANOVA * indicates P<0.05 and *** indicates P<0.01. NS indicates no significance 
difference). (D) Representative images of neuron, astrocyte, oligodendrocyte and NG2 cell. (E-F) 
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Kaplan-Meier survival curves and representative appearance of tumor bearing brains.  Log rank 
test showed no difference in survival across all groups. (G-K) Characterization of tumors 
induced by PBCAG-HRasV12/AKT. (G) Subarachnoidal spread of tumor cells (H&E). (H) 
Necrosis (black arrow, H&E).  (I-K) Tumor cells with fibrillary processes were positive for 
GFAP, vimentin and MAP2. (L-P) Characterization of tumors induced by PBGFAP-
HRasV12/AKT. (L) Overview of H&E staining. Black arrow indicates vessels. (M) Necrosis 
(black arrow).  (N-P) GFAP, Vimentin and MAP2 positive processes.  (Q-U) Characterization of 
tumors induced by PBMBP-HRasV12/AKT. (Q) Prominent oligodendroglial components (H&E).  
(R) Round cell appearance of tumor cell (inset) and mitosis (black arrow, H&E).  (S) GFAP 
positive astroglial process.  (T) Oligodendroglial cells were vimentin negative while astroglial 
elements were vimentin positive.  (U) MAP2 positive oligodendroglial component (black arrow, 
inset) and MAP2 positive astrocytes component (gray arrow). 
Scale bar: 200µm in A,B, L-N, P, Q, S;  100µm  in G, I-K and ; 50µm in H, O, R, T; 20µm in D 
and 10µm in inset in R and U. 
 
 
Expression of basic helix-loop-helix transcription factors modifies tumor type  
 Next we addressed whether addition of neurogenic transcription factors, Neurogenin2 
(Ngn2) and Neuronal Differentiation1 (NeuroD1) known to alter the fates of neural progenitors 
(Cai et al., 2000) would change tumor phenotype. We chose Ngn2 and NeuroD1 because they 
have been previously shown to block the differentiation of neural progenitors into astrocytes and 
to promote differentiation into neurons (Cai et al., 2000).  We hypothesized that transcription 
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factors with neuron promoting effects would either inhibit tumor formation, or result in the 
formation of tumors distinct from CAG donor plasmid induced tumors.  Indeed, expression of 
either Ngn2 or NeuroD1 along with the CAG donor plasmids resulted in a distinct tumor type 
that we never observed with any of the three other tumor inducing plasmid combinations. 
Furthermore, animals transfected with the Ngn2 or NeuroD1 modifying plasmids showed earlier 
death and higher rates of death than the other tumorigenic plasmid conditions (Figure 3-3A) Log-
rank tests showed animals transfected with Ngn2 or NeuroD1 modifying plasmids had 
significantly shorter survivals  (P<0.0001) than animals transfected with CAG, GFAP or MBP 
donor plasmids (Figure 3-3A). 
 Upon postmortem analysis of cerebral tumors in Ngn2 and NeuroD1 donor plasmid 
conditions we encountered large cerebral tumors with highly irregular surfaces by 14 days of age 
(Figure 3-3B).  Histologically these large tumors contained cells that were poorly differentiated 
and showed regions of extensive necrosis and proliferative features. The tumors contained 
prominent rhabdoid cellular elements demonstrated in H&E sections (black arrow in Figure 3-3H 
and L). The overall immunhistochemical profile indicated teratoid characteristics. Cells had 
characteristic‚“capping”-type expression patterns of Vimentin (black arrow in Figure 3-3I), and 
some cells were strongly positive for Actin (Figure 3-3J). There was also focal expression of 
epithelial membrane antigen (Figure 3-3K). We also did not observe significant expression of 
cytokeratin (Lu-5 epitope). Nuclear expression of INI (hSNF5/SMARCB1) was preserved in 
cells in these tumors. While poorly differentiated, the tumors showed regions of focal expression 
of astroglial GFAP (Supplementary Figure 4B, Supplementary Figure 5C) and Vimentin positive 
processes (Figure 3-3I,M) as well as scattered positivity for the neuronal markers MAP2 
(Supplementary Figure 3-4D, Supplementary Figure 5B) and synaptophysin (Supplementary 
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Figure 3-4C). Intriguingly, synaptophysin positivity marked areas and clusters of tumor cells 
with cytologically neuronal features. The non-organoid distribution of respective elements 
argues against entrapped neurons. MAP2c expression appeared to reflect dendritic neuronal 
structures. In sum, the tumors induced by combining Ngn2 or NeuroD1 donor plasmids with the 
CAG donor plasmid histologlically most resembled atypical teratoid rhabdoid tumor (ATRT) 
like tumors.  
Hertwig et al (Hertwig et al.) has reported that a panel of 7 signature genes can be used in 
error freely classification of three CNS tumors: glioma, PNET and ATRT. We therefore assessed 
the expression of this panel of 7 genes in the tumors induced by HRasV12/AKT in combination 
with Ngn2. We found significant up-regulation in the expression of 6 out of 7 genes in the 
tumors induced by HRasV12/AKT in and Ngn2 (Supplementary Figure 6). Among the 6 up-
regulated genes, SPP1, which has been suggested as a diagnostic marker to distinguish ATRT 
from PNET and medulloblastoma (Kao et al., 2005) and as grade indicator of glioma(Toy et al., 
2009), showed the greatest up-regulation (6.6 fold).  The pattern of gene up-regulation combined 
with the histological features suggest that the tumors induced by HRasV12/AKT in combination 
with Ngn2 or NeuroD1 are ATRT-like tumors.  
As the bHLH transfection conditions resulted in a unique and highly lethal tumor we next 
addressed whether this apparent phenotypic transformation from GBM to ATRT like tumors was 
due to a transient expression of bHLH factors in radial glia progenitors or to expression in tumor 
cells. The piggyBac transposon system allows for gating whether a transgene is integrated into a 
transfected cells or whether it remains episomal and is thus lost in cells that undergo subsequent 
proliferation (Chen and LoTurco, 2012). We substituted the Ngn2 donor plasmids used above 
with a plasmid, CAG-Ngn2, in which the CAG-Ngn2 transgene is not flanked by ITR sequences 
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and so is not subject to transposase-mediated genomic integration (Chen and LoTurco, 2012). As 
a result, transgene expression from these episomal plasmids is lost in 1-2 cell divisions (Chen 
and LoTurco, 2012; Siddiqi et al., 2014). Addition of episomal CAG-Ngn2 was sufficient to 
produce tumors (Supplementary Figure 3, Figure 3-3C-E) with clusters of tumor cells expressing 
epithelia membrane antigen (Figure 3-3F) and isolated cells expressing cytokeratin (Lu-5 epitope, 
Figure 3-3G). Nuclear INI1 was also preserved (data not shown). Thus, transient expression of 
Ngn2 in radial glial progenitors and their immediate progeny is sufficient to produce ATRT-like 
tumors.  
Figure 3-3 ATRT like tumor was induced by addition of Ngn2 or NeuroD1 to PBCAG-
HRasV12/AKT 
(A, B) 
Kaplan-Meier survival curves and representative images of ATRT like tumor bearing brains. 
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ATRT like tumor bearing animals had significantly short survival compared to GBM and 
anaplastic oligoastrocytoma bearing animals (log-rank test ,* indicates P< 0.05, *** indicates 
P<0.01). (C-G) ATRT like tumor is induced by addition of CAG-Ngn2 to PBCAG-
HRasV12/AKT mixture. (C) Rhabdoid components (black arrow, inset), neuronal differentiation 
(grey arrows, H&E).  (D) Vimentin rhabdoid cellular elements (black arrow, inset), and 
processes/glial differentiation (grey arrows).  (E) Individual cells were actin positive. (F) 
Clusters of cells express epithelial membrane antigen.  (G) Few cells were positive for 
cytokeratin (Lu-5 epitope). (H-K) ATRT like tumor is induced by addition of PBCAG-NeuroD1 
to PBCAG-HRasV12/AKT mixture. (H) Necrotizing tumor with mitoses, rhabdoid cellular 
differentiation (black arrow, inset), process rich and epitheloid portions (H&E). (I)Vimentin 
positive rhabdoid components (black arrow, inset) as well as Vimentin positive processes (grey 
arrow). (J) Actin positive cells. (K) Epithelial membrane antigen – clusters of positive cells. (L-
N) ATRT like tumor is induced by addition of PBCAG-Ngn2 to PBCAG-HRasV12/AKT 
mixture. (L) H&E – tumor with high cellularity and undifferentiated appearance (mitotic figure – 
grey arrow; rhabdoid cell - black arrow, inset). (M) Vimentin staining, individual rhabdoid 
components (black arrow, inset) in an environment of a glial process rich meshwork. (N) 
Clusters of actin positive cells. 
Scale bar: 100µm in C and E-N and 50µm in D and 10µm in all insets. 
 
Distinct developmental patterns of tumors 
The four tumor inducing conditions we describe above (CAG donor plasmid, GFAP donor 
plasmid, MBP donor plasmid, and CAG donor plasmid with a bHLH transcription factor 
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modifying donor plasmid) each produced histologically distinct tumors when assessed at similar 
postnatal developmental time points.  We next sought to address whether these differences might 
be reflected in differences in the developmental time course of each tumor type.  As shown in 
figure 3-4 A-E, we found that the CAG donor plasmid condition resulted in very early signs of 
abnormal cell proliferation with large aggregates of fluorescently labeled cells invading striatum 
and the ventricular and subventricular zones of neocortex by the day of birth (P0) in all animals 
examined (3/3) . In contrast, aggregates of proliferative cells were not apparent in either the 
GFAP (0/3) or MBP donor plasmid (0/3) condition in the first few days after birth (P2-P3; Figure 
3-4 F,K), but instead normally differentiating neurons were apparent a few days after birth with 
only scattered cells outside of the neuronal cortical plate.  By the end of the first postnatal week, 
masses of aberrantly proliferating cells appeared in both the MBP and GFAP donor plasmid 
conditions (Figure 3-4G, L) (3 out of 3 animals in MBP, GFAP donor transfected animals 
respectively).  These masses were often of a single clonally labeled color and were present in 
areas centered within white matter and the sub-pial zone (Figure 3-4 G,L). The time course of 
tumor growth was similar in the MBP and GFAP donor plasmid conditions, however as 
indicated in the histopathological analysis the morphology of cells in the two conditions differed 
in morphology by P21 (Figure 3-4 H, I, J, and M, N, O). In spite of the delayed appearance of 
large tumors in the GFAP and MBP donor plasmid conditions relative to the CAG donor plasmid, 
the size of tumors in the MBP and GFAP donor plasmid conditions by P21 reached sizes larger 
than those in the CAG donor plasmid condition (Figure 3-4C, H, M). Finally, consistent with the 
early lethality and highly aggressive nature of the tumors induced by CAG donor plasmids with 
addition of Ngn2 modifying plasmid, the tumors in this condition (Figure 3-4, P-U) were obvious 
by the day of birth (4/4) and expanded rapidly into very large tumors with street-like necroses 
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invading the entire cerebral hemisphere by three weeks after birth (7/7). The developmental 
patterns observed are consistent with when the promoters expressing the oncogenes are most 
active, the ubiquitous CAG promoter is strongly active early in progenitors while the GFAP and 
MBP promoters are most active latter in the lineage when glial cells begin differentiating.  
Figure 3-4 Induced tumors show distinct developmental time course 
(A-E) 
Developmental time course for PBCAG-HRasV12/AKT induced tumor. (A) Densely packed 
cells were found in VZ/SVZ, striatum, neocortex and pia at P0. Magnified view of boxed area is 
shown in A’. (B) Necrosis at P7. Magnified view of boxed area is shown in B’. (C) 
Representative image of PBCAG-HRasV12/AKT transfected brain at P21. (D) Edge of PBCAG-
HRasV12/AKT induced tumor. DAPI is shown in magenta. (E) Bipolar long spindle cells in 
PBCAG-HRasV12/AKT induced tumors. (F-J) Developmental time course for PBGFAP-
HRasV12/AKT induced tumor.  (F) A representative section from a P2 brain transfected with 
PBGFAP-HRasV12/AKT. Magnified view of boxed area is shown in F’. (G) P9 section from 
PBGFAP-HRasV12/AKT transfected brain. Magnified view of boxed area is shown in G’. (H) 
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Representative image of PBGFAP-HRasV12/AKT transfected brain at P21. (I) Edge of 
PBGFAP-HRasV12/AKT induced tumor. DAPI is shown in magenta. (J) Bipolar pyramidal cells 
with long processes in tumors induced by PBGFAP-HRasV12/AKT (K-O) Developmental time 
course for PBMBP-HRasV12/AKT induced tumor. (K) A representative section from a P3 brain 
transfected with PBMBP-HRasV12/AKT. Magnified view of boxed area is shown in K’. (L) P7 
section from PBMBP-HRasV12/AKT transfected brain. Magnified view of boxed area is shown 
in L’. (M) Representative image of PBMBP-HRasV12/AKT transfected brain at P21. (N) Edge 
of PBMBP-HRasV12/AKT induced tumor. DAPI is shown in magenta. (O) Small round cells 
with short processes in tumors induced by PBMBP-HRasV12/AKT. (P) A representative image 
section from a brain transfected with PBCAG-Ngn2, PBCAG-HRasV12/AKT at P0. Magnified 
view of boxed area is shown in P’. (Q) A section from P21 animal showed tumor cells spreading 
whole cerebral hemisphere. (R) Edge of tumor induced by PBCAG-Ngn2, PBCAG-
HRasV12/AKT. DAPI is shown in magenta. (S-T), Tumor cells frequently found in PBCAG-
Ngn2, PBCAG-HRasV12/AKT induced tumors. (U) Extensive street like necrosis. 
Scale bar: 1000µm in C, H, M and Q; 500µm in B, G, L and P; 200µm in A, F and K; 100µm in 
B’, D, G’ I, L’, N, P’, T, U; 50µm in A’ E, F’, K’J, O, S and T. 
 
 
Gene expression differences in tumor types 
The Cancer Genome Atlas research network (TCGA) identified 4 subtypes of glioblastoma 
multiforme subtypes by gene expression profiles and gene mutation (Verhaak et al., 2010). 
Through this analysis a group of 24 signature genes was identified that could be used to 
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categorize the 4 subtypes (Verhaak et al., 2010).  We therefore used expression levels of these 24 
signature genes to further assess whether the four tumor patterns produced in our study could be 
distinguished based on the expression of this set of genes. To do this, we used q-PCR and 
unsupervised hierarchical clustering analysis to compare and categorize the tumors produced by 
the four conditions. We found, consistent with the agreement in histopathological analysis, that 
the tumors produced by the CAG and GFAP donor plasmids clustered together in terms of 
expression of the 24 genes (Figure 3-5). The tumors that were most distinct in histopathology, 
those produced by the MBP donor plasmids and modified by the Ngn2 donor plasmids, differed 
in gene expression patterns relative both to each other and to the CAG and GFAP donor plasmid 
conditions (Figure 3-5). EGFR is frequently amplified and overexpressed in human GBMs; 
however, EGFR transcript was not prominent in all tumor types. This might be because 
Ras/AKT are downstream factors of EGFR pathway (Marumoto et al., 2009). We also found p53 
was neither mutated nor deleted (data not shown) and p53 transcript showed about 2 fold of up 
regulation.  Thus, the heterogeneity we find in tumors produced by differing promoter conditions 
and modifying transcription factor expression are also reflected in different gene expression 
patterns. 
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Figure 5 Induced tumors show different molecular signature 
(A) 
Unsupervised cluster analysis of qRT-PCR based gene expression data for 24 genes selected 
from Verhaak et al (Verhaak et al.) across different donor plasmids induced tumors. Heat map 
shows fold change in gene expression in induced tumors relative to tumor free brain tissues. The 
24 genes screened are listed on the left. Color scale represents fold changes of expression with 
red indicating up regulation and green indicating down regulation of gene expression. Gene 
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expression across 4 conditions was shown in rows and expression of the whole set of 24 gene in 
each tumor sample was shown in columns. (B) Averaged fold of regulation for 6 representative 
genes selected from (A). Error bar indicates standard error of mean (SEM). (One way ANOVA, 
* indicates P<0.05, *** indicates P<0.01). 
 
Discussion 
  Two, not mutually exclusive, explanations of tumor heterogeneity have been proposed 
(Visvader, 2011). Overwhelming experimental and clinical evidence show that different genetic 
mutations result in different tumor types including different CNS tumor types (Sieber et al., 
2005). For example, Hertwig et al (Hertwig et al., 2012) showed that infection of postnatal 
mouse neural stem cells with viruses containing V12HRAS or c-MYC could result in formation 
of 3 different tumor types depending upon the combination and sequence in which oncogenes 
were introduced. Similarly, Jacques et al (Jacques et al., 2010) showsed that different 
combinations of conditional genetic deletions in p53, Rb and PTEN in mouse subventricular 
zone neural stem cells could induce formation of either PNET or glioma.  Evidence for differing 
cell types being a source of CNS tumor heterogeneity has also been found (Brown et al., 1998; 
Gibson et al., 2010; Ince et al., 2007; Swartling et al., 2012). For example, transduction of 
mutationally stabilized N-Myc into neural stem cells from perinatal murine cerebellum and brain 
stem resulted in formation of medulloblastoma/primitive neuroectodermal tumors, while N-Myc 
transduced into NSCs isolated from forebrain resulted in diffuse glioma tumors (Swartling et al., 
2012). As different neural progenitor types have different gene expression profiles that may 
modify tumor cell differentiation it seems likely that both cell of origin and differences in gene 
mutation contribute to tumor type diversity in the CNS  (Visvader, 2011). Our study indicates 
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that in the developing neocortex cell populations of origin can contribute to tumor diversity, and 
moreover, that expression of non-oncogenic transcription factors expressed in the same 
population can also modify tumor type. 
Although pediatric GBM shares histological similarities with adult GBM, they are now 
thought to be different entities with different molecular characteristics (Paugh et al., 2010; Sturm 
et al., 2012). It has been shown, for example, that pediatric GBM display a spectrum of copy 
number variations distinct from adult GBM (Bax et al., 2010). Integrated molecular profiling 
experiments also reveal differences between pediatric and adult GBM. For example, IDH hotspot 
mutations are frequently found in adult high grade glioma but not in pediatric tumors (Paugh et 
al., 2010; Sturm et al., 2012). In addition, whereas PDGFRA is the predominant target of focal 
amplification in pediatric high grade glioma, in adult glioblastoma EGFR is the most common 
target (Paugh et al., 2010). Moreover, histone H3.3 mutations are frequently found in pediatric 
GBM while they are absent in adult GBM (Schwartzentruber et al., 2012; Sturm et al., 2012). 
The cell of origin of pediatric GBM is unknown and might be different from adult GBM as well. 
We have used the CAG donor plasmids to induce GBM which appeared as early as P7 in the rat 
and shows necrotic areas as early as at P4 a developmental time period in the precocial rat that 
corresponds to the neonatal period in human. Future experiments will be needed to determine 
whether the early arising tumors modeled in this system are more similar to pediatric or adult 
GBM in their molecular identity and cell of origin. 
Our study indicates that the cell of mutation for both ATRT like and GBM can be radial glial 
cells of embryonic neocortex.  The in utero electroporation method we used targets radial glia 
and radial neural progenitor cells that line the lateral ventricles of the lateral forebrain. This 
population of progenitors at the ventricular surface of E14/15 rat forebrain contains sub-
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populations of progenitors capable of generating neurons of different types, and primarily glia or 
primarily neurons (Siddiqi et al., 2014). We used the ubiquitous CAG donor plasmid to induce 
expression of HRasV12 and AKT immediately in the radial progenitor population. Ngn2 or 
NeuroD1 expressed by the same immediately active promoter was sufficient to change the tumor 
type generated. The tumor difference was apparent as early as the day of birth, approximately 
one week after induced gene expression.  We also found that transient expression of Ngn2 (by a 
non-donor episomal plasmid) in radial glia was sufficient to produce ATRT like tumors. The 
effectiveness of transient Ngn2 expression, in combination with previous findings that Ngn2 or 
NeuroD1 expressed in glioma cells induces cell death and neuronal differentiation without 
changing tumor type (Guichet et al., 2013; Zhao et al., 2012) supports the idea that Ngn2 and 
NeuroD1 acts in early stage radial progenitors to change the type of tumor generated. We have 
co-expressed Ngn2 with GFAP donor plasmids and found the resulted tumors were similar to 
tumors induced by GFAP donor plasmids alone. But we did found rhabdoidal cells in the 
resulted tumors (data not shown). However, the results have to be interpreted with caution since 
the mouse GFAP promoter fragment is also active in radial glia. In the future, combining Ngn2 
with MBP donor plasmids may distinguish the time of action of Ngn2. 
Loss of function in the INI1 gene is believed to be a significant cause of ATRT in humans 
(Biegel, 2006). INI1 knockout mice develop tumors but these do not appear to be ATRT 
(Klochendler-Yeivin et al., 2000).  Hertwig et al (Hertwig et al., 2012) showed that 
transplantation of NSC/NPCs serially infected with c-MYC and V12HRAS could generate 
ARTR like tumors with gene expression profiles similar to human ATRT suggesting that in 
rodent models additional mutation types can lead to ATRT. Similarly, we demonstrated in this 
study that ATRT like tumors are generated by HRasV12 and AKT transfection of neocortical 
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radial glia, but only when co-expressed with the bHLH transcription factors Ngn2 or NeuroD1, 
two genes that on their own are non-oncogenic. This underscores the strong possibility that 
tumor type diversity may be influenced not only by the cell of mutation but also by the specific 
molecular context present in that cell. 
Our current results also show that the GFAP and MBP promoter-active populations in the 
radial glia lineage generate tumors with different molecular and histological features. 
Interestingly, all cell types are labeled by the GFAP and MBP donor plasmids, but yet the tumor 
types generated were consistently different in histology and molecular signature.  This may 
suggest that tumor diversity is determined by the predominant cell type in a population that 
undergoes transformation. By mixing the GFAP and MBP donor plasmids in future experiments 
and tracking their clonal expansion we may be able to distinguish whether one tumor cell 
population is dominant over the other.  
 Several attributes of piggyBac transposon system demonstrated here make this model 
potentially useful for a variety of novel applications in tumor biology.  The main advantage of 
the piggyBac IUE method is that it allows for introduction of multiple transgenes. In this study, 
for example, we simultaneously introduced a transposase helper plasmid to target stable 
transgenesis in GLAST positive cells, two oncogene expressing donor plasmids with their own 
promoters, 3 fluorescent reporter genes (Figure 1, 2 and 3), and a transcription factor. The high 
coexpression efficiency allowed us to direct expression in different subpopulations in sequence, 
introduce a clonal labeling method, and a modifying transcription factor. This functionality 
should make this approach a useful platform for screening potential modifiers of tumor 
development and for determining further how genetic modifiers alter tumor development. 
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Methods 
Plasmids 
A system of piggyBac transposon donor and helper plasmids were produced and used in this 
study. To make the donor plasmid PBCAG-HRasV12 and PBCAG-AKT, HRasV12 was PCR 
amplified from pTomo (Marumoto et al., 2009) (Addgene plasmid 26292), human AKT was 
amplified from 1036 pcDNA3 Myr HA Akt1, (Ramaswamy et al., 1999) (Addgene plasmid 9008) 
respectively and inserted into the EcoRI/NotI sites of pPBCAG-eGFP (Chen and LoTurco, 2012). 
For construction of PBGFAP-HRasV12/AKT, PBMBP- HRasV12/AKT, HRas-V12 and AKT 
were inserted into EcoRI/NotI sites of PBGFAP-GFP and PBMBP-GFP respectively (Chen and 
LoTurco, 2012). For the bHLH donor plasmids PBCAG-Ngn2 and PBCAG-NeuroD1, human 
Neurogenin2 cDNA clone (IMAGE ID 5247719), human Neuronal differentiation1 cDNA 
(IMAGE ID 3873419) were purchased from Open Biosystem, PCR amplified and inserted into 
PBCAG-eGFP EcoRI/NotI sites. CAG-Ngn2 was made by inserting Ngn2 coding sequence into 
EcoRI/NotI sites of pCAG-eGFP. 
 
Animals 
Pregnant Wistar rats were obtained from Charles River Laboratories, Inc. (Wilmington, MA) 
and maintained at the University of Connecticut vivarium on a 12 h light cycle and fed ad 
libitum. Animal gestational ages were determined and confirmed during surgery. Both male and 
female subjects were used for tumor induction. For the purpose of constructing survival curves 
(Figures 2A, 3A) rats were removed from the experiment for humane purposes when they 
became unable to eat or drink. At the end of the 40 week survival experiment, percentage of 
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survival for each preceding week was calculated and % survival curves were generated. For 
tumors induced by PBCAG-Ngn2/PBCAG-HRasV12/AKT and PBCAG-NeuroD1/PBCAG-
HRasV12/AKT, survival rates were also calculated for each day. To statistically compare 
survival rates a log rank test, Breslow test and Tarone-Ware test were performed using SPSS 
(IBM SPSS statistics 21).  All procedures and experimental approaches were approved by the 
University of Connecticut IACUC. 
 
In utero electroporation 
In utero electroporation was performed as previously described (Chen and LoTurco, 2012). 
Electroporation was performed at embryonic day 14 or 15 (E14 or E15) and gestation age was 
confirmed during surgery. All plasmids were used at the final concentration of 1.0 μg/μl except 
PBCAG-CFP and GLAST-PBase were used at the final concentration of 2.0 μg/μl.  
 
Image acquisition and 3D reconstruction 
Multi color imaging was performed as described using Zeiss Axio imager M2 microscope 
with Apotome with 488/546/350 nm filter cubes and the X-Cite series 120Q light source (Siddiqi 
et al., 2014). All the images were further processed in Adobe Photoshop CS3 software (San Jose, 
CA). For 3D reconstruction, P27 Wistar rats were deeply anesthetized with Isoflurane and 
perfused transcardially with 4% paraformaldehyde/PBS (4% PFA). Samples were post fixed 
overnight in 4% PFA and sectioned at 65 µm thickness on vibratome (Leica VT 1000S). 
Sections were mounted onto microscope slides in sequential order, all aligned in the same dorsal-
ventral and left-right arrangement.  Images were acquired with Stereo Investigator (Microbright 
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Field, VT).  After imaging acquisition, outlines of the cerebral hemisphere and tumor clones 
were traced using color-coded contours for the hemisphere and each clone. Then traced images 
were transferred to Neurolucida Explorer (Microbright Field, VT), in which several contours 
from sequential sections were appended to one another, and organized and stacked in order. 3D 
model was created using Neurolucida Explorer software 3D visualization option to visualize the 
clonality of selected clones of tumor cells.  
 
Immunohistochemistry 
Animals were deeply anesthetized with Isoflurane and perfused transcardially with 4% 
paraformaldehyde/PBS (4% PFA). Samples were post fixed overnight in 4% PFA. For 
immunofluorescence, brains were sectioned at 65 µm thickness on a vibratome (Leica VT 
1000S). Sections were processed as free-floating sections and stained with GFAP (Cell Signaling, 
3670X), CC1 (Calbiochem, OP80) and NG2 (Chemicon, AB5320) antibody. Images were 
acquired and processed as previous described (Chen and LoTurco; Siddiqi et al.). 
For histological analysis, immnunohistochemsitry and H&E staining were carried out on 
paraffin embedded 4µm sections as described in (Schick et al., 2007a; Schick et al., 2007b) using 
GFAP (DAKO, Z0334), MAP2c (Sigma, M4403), Vimentin (DAKO, M0725), Synaptophysin 
(DAKO, M0776), Cytokeratin (BMA Medicals, T-1302), Actin (DAKO, M0851), epithelial 
membrane antigen (DAKO, M0613) antibody.  
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Tumor cell culture 
Tumors were dissected from PBCAG-HRasV12/AKT transfected animals at the age P21. 
After dissection, tumor tissues were chopped and trypsinized into single cell suspension. Then 
cells were cultured in a serum-free medium consisting of DMEM with L-glutamine, sodium 
pyruvate, B-27, N-2, bFGF and EGF (Invitrogen, CA). 2 days later, tumor cell adherent cultures 
were passaged into neurosphere suspension cultures at a density of 10cells/μl and allowed to 
grow for 3 days to form tumor spheres.  
 
RNA extraction, cDNA synthesis and qRT-PCR 
Animals aged P21 to P27 were deeply anesthetized with isoflurane. Brains were quickly 
removed on ice. Tumors were identified on the brain surface, removed and then chopped into 
cubes. Tissue from the opposite hemisphere that was tumor free was used as control. RNA 
extraction was performed using Ambion® RNAqueous® Kit (Invitrogen, CA) according to 
manufacturer’s instructions. cDNA synthesis was performed using Transcriptor First Strand 
cDNA synthesis kit (Roche) following manufacture’s protocol. qRT-PCR was performed using 
Fast SYBR® Green master mix (Applied Biosystem, CA). Primer sequences are listed in 
Supplementary Table 1. Triplicates were included from each sample. Fold of regulation of gene 
expression was calculated using ΔΔCt method. More specifically, the Ct values obtained from 
tumor and control brain RNA samples are directly normalized to a housekeeping gene (GAPDH). 
ΔΔCt is the difference in the ΔCt values between the tumor and control samples. The fold-
change in expression of the gene of interest between the tumor and control brain is then equal to 
2^ (-ΔΔCt). Unsupervised hierarchical clustering was performed on fold of regulation for each of 
the 24 genes profiled and a heat map was generated using the clustergram command in the 
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MATLAB bioinformatics toolbox (Math Works, MA). Other statistical analyses were performed 
using KaleidaGraph version 4.0 (SynergySoftware 2006). A confidence interval of 95% (p < 
0.05) was required for values to be considered statistically significant. All data are presented as 
means and standard error of the mean (SEM). 
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Chapter 4 Modeling Neurodevelopmental Disorder and Glioblastoma multiforme Using 
CRISPR/Cas9 System 
Abstract 
Tools for somatic cell transgenesis are important for modeling human somatic mutation 
diseases. In this report, we developed a CRISPR-IUE approach combining the CRISPR/Ca9 
system and in utero electroporation approach to induce somatic mutations in cells in neural 
progenitor lineage and to model neurodevelopmental disorder as well as glioblastoma 
multiforme. We first designed guide sequences targeting rat PTEN. The PTEN CRISPR 
constructs successfully abolished PTEN expression in neuron. Moreover, PTEN null neurons 
demonstrated phenotypes that were similar to PTEN knockout or knockdown neuron, including 
hypertrophy and altered membrane properties. At last, tumors resembling human glioblastoma 
multiforme were induced by combinations of three CRISPR constructs targeting rat PTEN, NF1 
and P53. These results demonstrated the utility of CRSIPR/Cas9 system in studying neocortical 
development as well as in modeling human genetic disease caused by somatic mutations. 
Introduction 
Most of human genetic diseases including cancers and neurological disorders are caused by 
somatic mutations {Bamford, 2004 #16;Futreal, 2004 #18;Hua, 2003 #17;Poduri, 2013 #15}. For 
example, loss of function of tumor suppressor phosphotase and tensin homolog (PTEN) caused 
by somatic mutations have been found in various cancers including glioblastoma multiforme 
(Wang et al., 1997), breast cancer (Minobe et al., 1999), metastatic melanoma (Celebi et al., 
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2000). To fully understand pathology and effects of those somatic mutations, animal models 
bearing those somatic mutations are needed.  
Recent breakthrough in genome engineering techniques such as zinc finger nuclease (ZFN), 
transcription activator like effector nuclease (TALEN) and clustered regularly interspaced short 
panlindromic repeats (CRISPR) (Cong et al., 2013; Mali et al., 2013), especially the CRISPR 
system, have enabled precise genome engineering with unprecedented speed. The type II 
CRSIPR/Cas9 system is the most frequently used genome engineering tool and has been used to 
generate transgenic animals in multiple species (Cho et al., 2013; Gratz et al., 2013; Hai et al., 
2014; Yang et al., 2013), to induce or correct genetic mutations in vivo (Ding et al., 2014), to 
screen for genes involved in specific biological process (Shalem et al., 2014; Wang et al., 2014), 
to activate or repress gene expression (Cheng et al., 2013; Gilbert et al., 2013; Qi et al., 2013) 
and to isolate specific genomic regions of interest (Fujita and Fujii, 2013) or visualize specific 
genomic regions of interest (Chen et al., 2013). The multiplex CRISPR/Cas9 system has 
provided the technical platform to model human genetic diseases caused by somatic genetic 
mutations in animals.  
In utero electroporation (IUE) is an efficient approach to deliver multiple transgenes into 
neural progenitors in developing forebrain in rodent. It has been widely used in studies of 
neocortical development (LoTurco et al., 2009). When combined with DNA transposon system, 
for example piggyBac transposon system, we are able to use in utero electroporation to fate-map 
neural progenitors (Chen et al., 2014a; Chen and LoTurco, 2012; Siddiqi et al., 2014) as well as 
to model central nervous tumors (Chen and LoTurco, 2012). In this report, we developed a 
CRISPR-IUE approach combining the CRISPR/Ca9 system and in utero electroporation 
approach to induce somatic mutations in cells in neural progenitor lineage and to model 
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neurodevelopmental disorder as well as glioblastoma multiforme. We first designed guide 
sequences targeting rat PTEN. The PTEN CRISPR constructs successfully abolished PTEN 
expression in neuron. Moreover, PTEN null neurons demonstrated phenotypes that were similar 
to PTEN knockout or knockdown neuron, including hypertrophy and altered membrane 
properties. At last, tumors resembling human glioblastoma multiforme were induced by 
combinations of three CRISPR constructs targeting rat PTEN, NF1 and P53. These results 
demonstrated the utility of CRSIPR/Cas9 system in studying neocortical development as well as 
in modeling human genetic disease caused by somatic mutations. 
Results 
Loss of  PTEN expression caused by CRISPR induced somatic mutation 
To investigate the application of CRISPR system in central nervous system, we designed two 
guide RNAs (gRNAs) targeting rat phosphatase and tensin homolog (PTEN) exon 6 (E6) and 
exon 8 (E8) (Figure4-1A). We cloned these two sgRNAs in pX330 construct containing the wild 
type SpCas9 (Cong et al. 2013).  In vitro SURVEYOR assay showed both sgRNAs were able to 
introduce mutations at PTEN genomic loci (Supplementary Figure 4-1A).   
In utero electroporation is an efficient method to deliver multiple plasmids DNA into neural 
progenitor cells in developing forebrains thus are used to label and manipulate cells in neural 
progenitor lineage such as neuron, astrocyte and oligodendrocyte (Chen et al., 2014a; Chen and 
LoTurco, 2012; Siddiqi et al., 2014)  (Figure 4-1B).  To test whether gRNAs targeting PTEN 
were able to introduce mutation in vivo, we used in utero electroporation to deliver pX330-PTEN 
E6 and pX330-PTEN E8 into E14 neocortical neural progenitors in rat. Empty pX330 vector 
containing wild type Cas9 but no gRNA was used to as control for Cas9 activity and CAG-
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mRFP was used as transfection control. All plasmids were used at the concentration of 1.5µg/µl. 
1µg/µl CAG-eGFP was used to visualize transfection in all conditions.  To further demonstrate 
gRNA targeting PTEN can induce somatic mutation, we performed in vivo SURVEYOR assay 
on a P19 pX330-PTEN E6 transfected brain. As shown in Supplementary Figure4-1B, gRNA 
targeting PTEN exon 6 successfully induced mutations at PTEN locus in vivo.  
At P19, PTEN immuohistochemistry showed 86% (86/100) in pX330-PTEN E6 and 82 % 
(81/99) in pX330-PTEN E8 transfected neurons (GFP positive) were negative for PTEN (Figure 
4-1C, D). No PTEN negative neurons were found in pX330 and pCAG-mRFP transfected 
animals (data not shown). These results indicate gRNAs targeting PTEN exon 6 and 8 were able 
to introduce mutations in vivo at PTEN genomic loci and these mutations were able to abolish 
PTEN protein expression with high efficacy.  In pX330-PTEN E6 and E8 transfected brains, 
most of GFP labeled neurons migrated normally to proper laminar position layer II/III, whereas 
about 10% GFP labeled neurons were ectopically located in white matter (Figure 4-1E). This 
result is consistent with previous studies showing that migration defect only occurred in  subset 
of PTEN null neurons (Backman et al., 2001; Kwon et al., 2001; Zhu et al., 2012).  
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Figure 4-1 CRISPR knocks out PTEN expression in vivo 
 
A, Schematic of gRNAs targeting PTEN exon 6 and exon 8 
B, Schematic of in utero electroporation 
C-D, GFP+ PTEN negative neurons in pX330-PTEN exon 6 and exon 8 transfected brains 
E-F, Small population of neurons showed disrupted migration. 
 
PTEN mutated neurons were hypertrophic and showed altered membrane properties 
Consistent with previous reports of hypertrophy in PTEN deleted or knocked down neurons 
(Fraser et al., 2004; Kwon et al., 2001; Luikart et al.), neurons transfected with PTEN targeting 
gRNAs showed increased soma size (Figure 4-2A).  At P19, pX330 (212.7±5.7 µm
2
, n=85) and 
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CAG-mRFP (201.2± 5 µm
2
, n=74) transfected neurons had similar size (One way ANONVA, 
p=0.08) (Figure 4-2B).  Somas of pX330-PTEN E6 (453.8± 5.2 µm
2
, n=72) transfected neurons 
were significantly increased compared to neurons transfected with pX330 (One way ANOVA, 
p= 3.16671E-48) or CAG-mRFP (One way ANOVA, 8.97499E-58). Similarly, pX330-PTEN E8 
transfected neurons had average soma size of 428.5.3± 12 µm
2 
(n=88) and were significantly 
larger than neurons transfected with pX330 (One way ANOVA, p= 1.27038E-29) or CAG-
mRFP (One way ANOVA, p=1.58021E-36). However, pX330-PTEN E6 and E8 transfected 
neurons showed comparable sized soma (One way ANOVA, p= 0.097757973). 
To quantify the primary dendritic width, we measured the width of the primary dendrites at 
50µm to the center of the soma. Neurons transfected with CAG-mRFP and pX330 had similar 
primary dendritic width(CAG-mRFP, 2.9±0.2µm, n=14; pX330,2.8±0.2µm,(n=25; p=0.72 One 
way ANOVA) (Figure 4-2C). The primary dendritic width in pX330-PTEN E6 transfected 
neurons was 4.7±0.2µm (n=24) and was significantly larger than CAG-mRFP (One way 
ANOVA, p=3.70486E-06) and pX330 (One way ANOVA, p= 9.50806E-09) transfected neurons. 
Similarly, pX330-PTEN E8 transfected neurons had significantly thicker primary dendrite 
(5.4±0.2 µm n=18) than CAG-mRFP (One way ANOVA, p= 5.36052E-09) or pX330 (One way 
ANOVA, p= 3.99844E-12) transfected neurons. 
We then looked at the electrophysiological properties of transfected neurons. Neurons 
transfected with CAG-mRFP, pX330 and pX330-PTEN E8 had similar resting membrane 
potential (Figure 4-2D; CAG-mRFP,-74.99±3.5 mV, n=13; pX330,-72.98±2.6mV, n=6; pX330-
PTEN E8,-71.71±4.1mV, n=9; ANOVA with Turkey multiple comparison, ns). We found, 
consistent with the increased soma size in pX330-PTEN E8 transfected cortical pyramidal 
neurons, significantly decreased input resistance through whole cell recording(Figure 4-2E). The 
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input resistance for pX330-PTEN E8 transfected neurons were 44.03±3.566M Ω (n=7) and  were 
significantly lower than pX330 and CAG-mRFP transfected neurons (pX330: 76.66±5.941M Ω; 
ANOVA with Turkey multiple comparison, p<0.01, n=12; CAG-mRFP: 98.42 ±11.98M Ω, 
ANOVA with Turkey multiple comparison, p<0.01, n=6). No significant difference was 
observed between pX330 and CAG-mRFP transfected neurons (ANOVA with Turkey multiple 
comparison, ns).  
  We next looked at the spontaneous synaptic events. In control recordings, there were no 
differences between CAG-mRFP and pX330 transfected cortical pyramidal neurons (CAG-
mRFP: 5.025±0.9015Hz, n=6; pX330: 3.754±0.5996Hz, n=12; One way ANOVA with Turkey 
multiple comparison, ns) (Figure 4-2F). pX330-PTEN E8 transfected pyramidal neurons showed 
markedly increased spontaneous EPSC (sEPSC) frequency (8.273±1.009Hz, n=7; pX330-PTEN 
E8 vs pX330, p< 0.01; pX330-PTEN E8 vs CAG-mRFP, p<0.05, ANOVA with Turkey multiple 
comparison) (Figure 4-2F). Similarly, in the presence of tetrodotoxin, no differences in miniature 
EPSC (mEPSC) between CAG-mRFP and pX330 transfected pyramidal neurons were observed 
(CAG-mRFP, 1.334±0.1996Hz, n=6; pX330, 2.951±0.5272Hz, n=12; ANOVA with Turkey 
multiple comparison, ns) (Figure 4-2G). pX330-PTEN E8 transfected pyramidal neurons showed 
markedly increased mEPSC frequency (4.787±0.4990Hz, n=7; pX330-PTEN E8 vs pX330, p< 
0.05; pX330-PTEN E8 vs CAG-mRFP, p<0.01, ANOVA with Turkey multiple comparison) 
(Figure 4-2G). These results are consistent with previous reports on PTEN knockout or 
knockdown neurons using transgenic animals or shRNA and indicate that gRNAs targeting 
PTEN are highly specific and CRISPR/Cas9 can be used in vivo neuronal function studies. 
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Figure 4-2 PTEN null neurons showed hypertrophy and altered membrane properties 
 
A, Morphologies of neurons transfected with CAG-mRFP, pX330, pX330-PTEN E6 and pX330-
PTEN E8. 
B, Neurons transfected with pX330, pX330-PTEN E6 and pX330-PTEN E8 showed increased 
soma size. 
C, Neurons transfected with pX330, pX330-PTEN E6 and pX330-PTEN E8 showed thickened 
primary dendrites. 
D-E, Membrane properties of neurons transfected with pX330-PTEN E8.  pX330-PTEN E8 
transfected neurons had similar resting membrane potential as control neurons (D), decreased 
input resistance (E) and increased sEPSC (F) and mEPSC (G).  
(Eelectrophysiological experiments were performed by Alicia Yue Che ) 
Combination of CRISPR constructs targeting PTEN, NF1 and P53 induce tumor formation 
Loss of function of tumor suppressors caused by somatic mutations has been implicated in 
various cancers. We have showed that CRISPR/Cas9 system can induce mutation in targeting 
genomic locus in vivo.  We therefore hypothesized that loss of function of tumor suppressors 
mediated by CRSIPR/Cas9 system can lead tumor formation in vivo. To test this, we designed 
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two additional gRNAs targeting Neurofibromin 1 (NF1) exon 1 and P53 exon 6 and cloned them 
into pX330 vector, named pX330-NF1 E1 and pX330-p35 E6 respectively.  In vitro 
SURVEYOR assays showed both gRNAs were able to introduce mutations at targeted genomic 
locus (Supplementary Figure 4-2) and immunohistochemistry showed both gRNAs were able to 
abolish endogenous gene expression in neurons (Supplementary Figure 4-2B). 
We electroporated CRISPR constructs with gRNA targeting PTEN, NF1 and P53 alone or in 
combination with each other into E14 rat brains. PiggyBac plasmids (GLAST-PBase, PBCAG-
eGFP, or PBCAG-mRFP) were used to track the radial glia lineage. Episomal CAG-eGFP or 
CAG-mRFP was also used to distinguish experimental conditions (Figure 4-3 and 
Supplementary Figure 4-3). When looked at P19, in brains transfected with gRNAs targeting 
PTEN, P53 either alone or in combinations (Figure 4-3B, C, E and F; Figure Supplementary 
Figure 4-3B, C E and F), fluorescently labeled glia showed similar morphology and proliferation 
as in pX330 (Figure 4-3 A) transfected brains.  However, in brains transfected with gRNA 
targeting NF1 either alone or in combination with gRNAs targeting PTEN , increased glia 
proliferation was frequently observed. Large patches of densely packed fluorescently labeled cell 
were frequently found in neocortex and striatum. (Figure 4-3 D, G, H; Supplementary Figure 4-3 
D, G, H). These big patches of labeled glia were largely absent in either pX330 or gRNAs 
targeting PTEN and /or p53 transfected brains. This increased glia proliferation in pX330-NF1 
E1 transfectesd brains is consistent with previous report that deletion of NF1 induced glia 
prolieferation but no tumor formation (Fraser et al., 2004). 
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Figure 4-3 Loss of NF1 expression caused increase proliferation of glia. 
 
A, Representative image of P19 rat brain transfected with pX330 
B, Representative image of P19 rat brain transfected with pX330-PTEN E6 
C, Representative image of P19 rat brain transfected with pX330-PTEN E8 
D, Representative image of P19 rat brain transfected with pX330-NF1 E1. Note the increased 
density of labeled cells in neocortex and striatum. 
E, Representative image of P19 rat brain transfected with pX330-P53 E6.  
F, Representative image of P19 rat brain transfected with pX330-PTEN E8 and pX330-P53 E6. 
G, Representative image of P19 rat brain transfected with pX330-PTEN E8 and pX330-NF1 E1. 
Note the increased density of labeled cells in neocortex and striatum. 
H, Representative image of P19 rat brain transfected with pX330-P53 E6 and pX330-NF1 E1. 
Note the increased density of labeled cells in neocortex and striatum. 
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 However, in P19 brains transfected with CRISPR constructs targeting PTEN E8， P53 E6 
and NF1 E1, significant cell proliferation was observed as indicated by massive fluorescently 
labeled cells densely populating almost whole brain hemisphere (Figure 4-4A). The massive cell 
proliferation suggested the presence of tumor. We have previously established the multicolor 
lineage labeling approach using piggyBac transposon system (Siddiqi et al., 2014) and 
successfully labeled brain tumors (Chen et al., 2014a). We next electroporated the piggyBac 
multicolor system (GLAST-PBase, PBCAG-eGFP,PBCAG-mRFP and PBCAG-CFP) with 
CRISPR constructs targeting PTEN, P53 and NF1 to clonally label resulted tumor cells. 
Transfected animals showed sign of illness and started to demise at the age of P63. All animals 
(n=8) had died by P75. Upon postmortem analysis of transfected brains, we immediately noticed 
that transfected hemisphere was significantly enlarged indicating the presence of tumor.  Figure 
4-4B showed the multicolor tumor from a postmortem brain of a P63 rat. Tumor clones labeled 
with different colors were apparent. It is also noticeable that tumor cells can also be found in 
cerebral hemisphere that was not transfected indicating these tumors cell were highly migratory 
and invasive. It is also interesting to notice that tumor cells found in non transfected hemispheres 
were either in single colored clusters (Figure 4-4C) indicating that these tumor cells are clonally 
related or in mixed color clusters (Figure 4-4D) indicating  mixing of different tumor clones.  
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Figure4- 4 Multicolor labeling of CRISPR constructs induced tumor 
 
A, Representative image of CRISPR targeting PTEN, P53, NF1 from a P1 rat. 
B, Multicolor labeling of tumor cells 
C and D, enlarged view of boxed area in B. C showed separation of two tumor clones. D showed 
the mixing of different colored tumor clones. 
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Histopathological analysis revealed increased cell density in tumor core and tumors cells 
frequently were mitotic (Figure4-5 A). Tumor cells diffusely infiltrated neighboring tissue 
(Figure 4-5A, B) and exhibited glomeruloid vascular proliferation (Figure 4-5B) which is 
important histopathological features of human glioblastoma multiforme.   Several multinucleated 
large cells are visible in the tumor, suggesting the differential diagnosis of giant cell 
glioblastoma (Figure 4-5C black arrow). However, this cellular pattern was only occasionally 
observed, arguing against this differential diagnosis. Tumors cells demonstrated features for 
astroglial differentiation with strong vimentin (Figure 4-5D), GFAP (Figure 4-5E) and MAP2 
(Figure 4-5F) expression in a process rich pattern.  In summary, the histological features of 
induced tumors are most similar to human glioblastoma multiforme (WHO grade IV). In 
summary, we have successfully induced highly malignant glioblastoma multfiorme using 
CRISPR/Cas9 system. 
We further performed in vivo SURVEYOR assay using tumor genomic DNA. All three 
gRNAs introduced mutations at high efficacy at targeted geonic loci (Supplementary Figure4- 
4A). Sequencing of the the mutated PTEN allele showed that both insertions and deletions were 
induced and indels significantly altered the protein amino acids sequence downstream the double 
strand break sites (Supplementary Figure 4-4B). 
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Figure 4-5, Histological features of CRISPR constructs induced tumors 
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A) Diffusely infiltrating glial tumor with changing cellular densities and mitotic figure as sign of 
frank malignancy (black arrow). 
B) Pleomorphic diffusely infiltrating tumor with a process rich matrix and glomeruloid vascular 
proliferate (black arrow). 
C) Several multinucleated large cells are visible in the tumor, suggesting the differential 
diagnosis of giant cell glioblastoma (black arrow). However, this cellular pattern was only 
occasionally observed, arguing against this differential diagnosis. 
D) Tumor cells are strongly expressing vimentin in a process rich pattern. 
E) Tumor cells with characteristic expression of glial fibrillary acidic protein (GFAP) in a 
process-oriented pattern. 
F) Tumor cells in parallel show a similar expression pattern for MAP2. 
 
 
Discussion 
In this report, we have demonstrated the applications of CRSIPR/Cas9 system to abolish 
gene expression in developing neocortex and to model human neurodevelopmental disorder as 
well glioblastoma multiforme. To our knowledge, this is the first report of using CRSIPR/Cas9 
system to model human tumors and neurodevelopmental disorders.  This study revealed several 
features of CRISPR/Cas9 system which make it a powerful biological tool. 
    CRISPR/Cas9 system introduces mutations in vivo at targeting genomic locus and abolishes 
gene expression with high efficacy. gRNAs targeting two different exons of PTEN (exon 6 and 8) 
abolished PTEN expression in 86% and 82% of transfected neurons at P19 respectively. This 
high loss of expression efficiency of CRISPR/Cas9 system makes it an ideal tool to study gene 
function in vivo. 
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Genome wide binding assay of Cas9 in mammalian cells showed that dCas9 (mutant Cas9) is 
able to bind to genomic DNA even without the presence of gRNA (Wu et al., 2014).It is unclear 
that whether wild type Cas9 will cleave the genome without gRNA. It is critical to know whether 
wild type Cas9 can cause experimental artifact through random cleavage of genome without 
gRNA. We have compared membrane properties of neurons transfected with plasmid only 
contains wild type Cas9 but not gRNA (pX330) with neurons transfected with commonly used 
plasmid only encoding mRFP (CAG-mRFP) and found that neurons transfected with pX330 had 
similar membrane properties including resting membrane potential, sEPSC and mEPSC. 
Additionally, no migration defect was observed in neurons transfected with pX330. This 
suggests that at least wild type Cas9 doesn’t cause functional genomic changes that can affect 
resting membrane potential, eEPSCs, mEPSC and neuronal migration.  
Compared to shRNA, CRISPR/Cas9 is much more effective to knockout gene expression 
(Shalem et al., 2014). Like shRNA, CRISPR/Cas9 also suffers from off target effect. However, it 
is impossible to predict off target sites for shRNA, off target sites for CRISPR/Cas9 is 
predictable thus it is possible to assess whether mutations are introduced at off target sites. 
Functional off target can be avoided by choosing gRNAs don’t have off target sites in functional 
genes. The gRNAs used here all have no predicted off target in gene coding regions (data not 
shown). We also showed neurons transfected with two gRNAs targeting exon 6 and exon 8 of 
PTEN showed same phenotype, indicating the resulted phenotype is due to on target effect other 
than off target effect of gRNAs. We also showed that PTEN null neurons exhibited phenotypes 
similar to PTEN knockout or knock down neurons. These results indicate gRNA targeting PTEN 
is highly specific and the results generated from CRISPR system are comparable to results 
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obtained from shRNA or knockout studies. Of course CRISPR might also have off target effect 
in non-predictable sites; special attention is needed when assessing experiment results. 
    We have successfully induced glioblastoma multiforme using CRISPR/Cas9 system by 
targeting 3 tumor suppressor genes, PTEN, NF1 and p53.  This tumor model is highly malignant 
and invasive. In combination of multicolor labeling, this multi color GBM animal model will be 
ideal to study tumor cell migration.  Above all, we have demonstrated the application of 
multiplex CRISPR/Cas9 in modeling human somatic diseases. The ease of production, high 
efficacy will  make CRISPR/Cas9 system in studying brain development  in both normal and 
dseased state. 
 
 
Methods: 
Plasmids and gRNA sequence 
Guide RNA sequences were designed using on-line program (crispr.mit.edu) as described in 
(Hsu et al., 2013). Guide sequences were cloned into pX330 vector (Addgene plasmid 42230) 
{Cong, 2013 #4} following normal cloning procedure. The guide sequences are: PTEN exon 6 
forward: 5’- GATATACATAGCGCCTCTGAC-3'; PTEN exon 6 reverse: 5'-  
GTCAGAGGCGCTATGTATATC-3';PTEN exon 8 forward: 5’- 
ATTTGGAGAGAAGTATCGGT-3’; PTEN exon8 reverse: 5’-ACCGATACTTCT CTCCAA 
AT -3’; NF1 exon 1 forward: 5’-GGTCAGCCGCTTCGACGAGC-3’;NF1 exon 1 reverse 5’- 
GCTCGTCGAAGCGGCTGACC -3'; P53 exon 6 forward: 5’- 
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CTTCCACCCGGATAAGATGT-3’; P53 exon 6 reverse: 5’-ACATCTTATCCGGGT GGA 
AGC -3'.  
 
Animals 
Pregnant Wistar rats were obtained from Charles River Laboratories, Inc. (Wilmington, MA) 
and maintained at the University of Connecticut vivarium on a 12 h light cycle and fed ad 
libitum. Animal gestational ages were determined and confirmed during surgery. Both male and 
female subjects were used for tumor induction. All procedures and experimental approaches 
were approved by the University of Connecticut IACUC. 
 
In utero electroporation 
In utero electroporation was performed as previously described {Centanni, 2012 #41;Centanni, 
2014 #40;Chen, 2014 #5;Chen, 2012 #88;Chen, 2014 #37}. Electroporation was performed at 
embryonic day 14 or 15 (E14 or E15) and gestation age was confirmed during surgery. All 
plasmids were used at the final concentration of 1.0 μg/μl GLAST-PBase was used at the final 
concentration of 2.0 μg/μl.  
 
Image acquisition  
Multi color imaging was performed as previously described (Chen and LoTurco, 2012) using 
Zeiss Axio imager M2 microscope with Apotome with 488/546/350 nm filter cubes and the X-
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Cite series 120Q light source (Chen et al., 2014a)All the images were further processed in Adobe 
Photoshop CS3 software (San Jose, CA).  
 
Immunohistochemistry 
Animals were deeply anesthetized with Isoflurane and perfused transcardially with 4% 
paraformaldehyde/PBS (4% PFA). Samples were post fixed overnight in 4% PFA. For 
immunofluorescence, brains were sectioned at 65 µm thickness on a vibratome (Leica VT 
1000S). Sections were processed as free-floating sections and stained with PTEN (Cell Signaling, 
9559), NF1 (Santa Cruz, 9559) and p53 (Cell Signaling, 2524), antibody. Images were acquired 
and processed as previous described {Siddiqi, 2014 #150}. 
For histological analysis, immnunohistochemsitry and H&E staining were carried out on 
paraffin embedded 4µm sections as described in (Schick et al., 2007a; Schick et al., 2007b)using 
GFAP (DAKO, Z0334), MAP2c (Sigma, M4403), Vimentin (DAKO, M0725), antibody.  
SURVEYOR assay 
For in vitro SURVEYOR assay, rat neuroblastoma cells were transfected with CRISPR 
constructs using lippfectomine 2000 (Invitrogen) according to manufacturer’s instruction.  Two 
days post transfection, cells were harvested and genomic DNA was extracted using Blood and 
Tissue DNA easy kit (Qiagen). Genomic region flanking targeting sites were PCR amplified and 
SUVEYOR assay was performed using SURVEYOR assay kit (Transgenomics) according to 
manufacturer’s instruction.  For in vivo SURVEYOR assay, we freshly removed the brain and 
carefully dissected out transfected cortical region under fluorescent dissection microscope.  Brain 
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tissues were chopped into small pieces and genomic DNA was extracted using Blood and Tissue 
DNA easy kit (Qiagen). Primers for SURVEYOR assays are: PTEN exon 6 Forward: 
CATCCATGTGAGGAACCCTGGGTG; PTEN exon 6 Reverse: CACTTACTG 
CAAGTTCCGCC; PTEN exon 8 Forward: CCACAAGGTGTTTGCCTTCA; PTEN exon 8 
Reverse: CTCGAGATCCAAAGGCATTG; NF1 exon 1 Forward: 
GACGTCACCTCCAGGAGGAC; NF1 exon 1 Reverse: TGGGATAAAGGGGATGGAGGG; 
P53 exon 6 Forward: CCCACTTTGACCCTTGATCC; P53 exon 6 Reverse: 
CAGGCACAAACACGAACCTC. 
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Chapter 5 Summary and further discussion 
Summary  
This dissertation is aimed to develop new tools for radial glia lineage tracing and modeling 
central nervous system tumors. To this end, I first established the piggyBac in utero 
electroporation approach to label and manipulate the lineage of neural progenitors. I then used 
this piggyBac-IUE approach to establish new central nervous system tumor model. I further 
explored the sources of CNS tumor heterogeneity using this animal model. At last, I applied the 
newly developed RNA guided genome engineering tool CRISPR/Cas9 system to study 
neocortical development. Using CRISPR/Cas9 in utero electroporation approach, I have 
successfully modeled neural development disorder as well as glioblastoma multiforme.  In sum, I 
have established three novel methods which have been proven to be useful to study normal and 
diseased brain development.  
In Chapter 2, I took advantage of the features of in utero electroporation and piggyBac 
transposon system and established piggyBac-IUE approach to trace neural progenitor lineage. 
The piggyBac-IUE approach successfully labeled cells in the neural progenitor lineage including 
neurons, astrocytes, oligodendrocytes, oligodendrocytes precursors as well as olfactory bulb 
interneurons. I also constructed a modular piggyBac toolkit that can be used to label and 
manipulate neural progenitor lineage. As proof of principle, I also demonstrated of the utility of 
piggyBac IUE approach in gain of function experiment by over expressing EGFR.  
In Chapter 3, I first utilized the piggyBac IUE approach to induce brain tumors by over 
expressing two well studied oncogenes HRasV12 and AKT. Expression of HRasV12/AKT 
controlled by ubiquitous CAG promoter in piggyBac donor plasmids, induced glioblastoma 
multiforme in rat. To assess contributions of astrocytes and oligodendrocytes in brain 
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tumorigenesis, I expressed HRasV12/AKT in mainly astrocytes and oligodendrocytes using 
piggyBac GFAP and MBP donor plasmids respectively.  Expression of HRasV12/AKT in 
astrocytes induced glioblastoma multiforme, whereas expression of HRasV12/AKT in 
oligodendrocytes induced anaplastic oligoastrocytoma. This result indicates that cellular context 
contributes to tumor heterogeneity. Next, I co-transfected the tumor inducing piggyBac CAG 
donor plasmids together with neurogenic bHLH family transcription factor Ngn2 or NeuroD1 
and found that malignant pediatric atypical teratoid rhabdoid tumor like tumor was induced. This 
result indicates that molecular context also contributes to tumor heterogeneity. I further showed 
that tumors induced by piggyBac CAG donor plasmids, GFAP donor plasmids, MBP donor 
plasmids as well as CAG donor plasmids with modifying transcription factors showed distinct 
developmental time course and molecular signature.  Taken together, oncogenic events occurring 
in disparate cell types and/or molecular context leads to different tumor formation.  
In Chapter 4, I explored the feasibility of using CRISPR/Cas9 system to study brain 
development. I used in utero electroporation approach to deliver Cas9 together with gRNAs 
targeting PTEN exon 6 and 8 into developing rat forebrain.  Both gRNAs were able to introduce 
mutations into PTEN genomic loci and as a result, abolished PTEN expression with high 
efficiency in cells of the neural progenitor lineage. Moreover, PTEN null neurons showed similar 
phenotypes as neurons with knocked out or knocked down PTEN expression.  I next 
demonstrated application of CRISPR/Cas9 system to model human brain tumor. In utero 
electroporation of plasmids mixture of Cas9 and gRNAs targeting three tumor suppressors PTEN, 
NF1 and P53 induced glioblastoma multiforme.   
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Features of piggyBac IUE  
Key attributes of piggyBac transposon system and in utero electroporation method make 
this approach innovative and potentially useful for a variety of applications. First, in utero 
electroporation with piggyBac plasmids overcome the loss of conventional episomal plasmids in 
IUE, thus making neural progenitor lineage labeling possible (Chen et al., 2014a; Chen and 
LoTurco, 2012; Chen et al., 2014b; Siddiqi et al., 2014).  Second, piggyBac has larger cargo 
capacity. Ding and colleagues (Ding et al., 2005) have reported piggyBac can carry up to 14.3Kb 
insert without affecting the transposition efficiency. Lacoste and colleagues (Lacoste et al., 
2009)reported that the engineered piggyBac called “ePiggyBac” could deliver up to 18Kb inserts. 
Rostovskaya et al used piggyBac system to insert bacterial artificial chromosome into host 
genome (Rostovskaya et al., 2012). The large capacity makes it possible to deliver several 
transgenes into the genome (Yusa et al., 2009).Since 80% of human cDNA is less than 7kb 
(Lander et al., 2001),  piggyBac is able to deliver more than 80% of all human cDNAs. 
Compared to piggyBac, the cargo capacity for retroviral and lentiviral vectors is limited (Thomas 
et al., 2003).  
Third, in combination of piggyBac transposon system with episomal plasmid, immediate 
progenies in the lineage can be distinguished from the following progeny (Chen and LoTurco, 
2012; Chen et al., 2014b). This allows to express one transgene in only the birthdated progeny 
(first member of a lineage near the time of transfection) but not in the subsequent progeny of the 
lineage (Figure 2-1). 
Fourth, piggyBac IUE inherits features of spatial and temporal control of gene expression as 
well as multiple plasmids co-delivery conferred by in utero electroporation. Spatial control is 
achieved through spatially targeting cells within different areas (Chen and LoTurco, 2012; Chen 
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et al., 2014b)or cell type specific promoter driving gene expression(Chen et al., 2014a; Chen and 
LoTurco, 2012; Chen et al., 2014b; Siddiqi et al., 2014). PiggyBac IUE method allows for 
introduction of multiple transgenes controlled by independent promoters. The high co-expression 
rates allowed us to direct expression in different subpopulations in sequence (Figure 3-
3).Temporal control can be attained by transfection time and using inducible gene expression 
system. Precise temporal control of gene expression can now be achieved through piggyBac 
based inducible gene expression systems (Li et al., 2013; Saridey et al., 2009) gated by 
tetracycline. Therefore transgenes can be introduced embryonically but will not express until 
treated by tetracycline at desirable time depending on experimental need.  
Last, because piggyBac transposon system is binary, it is possible to direct genomic 
integration in a subset of progenitors by the choice of promoter driving the expression of PBase, 
and to drive expression of the integrated transgenes in selected progeny by the promoter in the 
donor plasmid. 
Limitations of piggyBac IUE approach comes from inherent limitation of IUE approach.  
IUE has been used to target cerebral cortex (Bai et al., 2003; Chen and LoTurco, 2012; Chen et 
al., 2014b; Maher and LoTurco) , hippocampus (Chen and LoTurco, 2012), as well as 
cerebellum (Kita et al., 2013)Other brain areas such as hypothalamus, brain stem are inaccessible 
using IUE. 
Applications of piggyBac IUE approach 
Using promoter fragments that are active in neural progenitors driving expression of PBase, 
it is possible to label lineage of neural progenitor subpopulations. Neural progenitor is highly 
heterogeneous (Kriegstein and Alvarez-Buylla, 2009). Lineage labeling of neural progenitor 
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subpopulation makes it possible to study functions and properties of neural progenitor 
subpopulations. For example, we have used GLAST and Nestin promoter fragments driving 
PBase expression (GLAST-PBase and Nestin-PBase) to label the lineage of GLAST+ and 
Nestin+ neural progenitors. Our results showed that GLAST+ neural progenitor generates not 
only more astrocytes, but also bigger astrocytes clonal clusters than Nestin+ neural progenitors 
do(Siddiqi et al., 2014).   
By mixing and matching piggyBac donor and helper plasmids with different promoters, it is 
also possible to label the lineage of subset of neural progenitors but only express transgenes in 
specific cell types within the lineage. For example, by using GLAST-PBase and PBGFAP-eGFP, 
I was able to label GFAP+ cells within the GLAST+ progenitor lineage (Figure 3-2A).  
PiggyBac IUE approach offers an effective way to manipulate cells within the neural 
progenitor lineage, i.e. neurons, astrocytes, oligodendrocytes, OPCs and olfactory bulb 
interneurons.  By using promoter of interest, we can direct transgene of interest expression in 
cells of interest. For example, using CAG promoter driving EGFR expression in piggyBac donor 
plasmid (PBCAG-EGFR), I was able to express EGFR in all cells in the progenitor lineage.  
Further, I directed oncogene HRasV12/AKT expression in astrocytes and oligodendrocytes using 
piggyBac GFAP and MBP promoter in piggyBac donor plasmids and induced different tumor 
types.   
Neuron - glia interaction has been long appreciated in regulating CNS homeostasis. 
PiggyBac IUE allows for independent labeling and manipulation of neurons and glia therefore it 
is an ideal tool to study neuron glia interaction in vivo.  Use piggyBac IUE, astrocytes can be 
manipulated as desired and evaluate its effect on neurons and vice versa.  
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Applications of piggyBac IUE CNS tumor model 
Using piggyBac IUE, I established novel somatic engineered CNS tumor model in rat in 
which determinants of CNS tumor diversity can be parsed out. In this animal model, I used the 
piggyBac multicolor system (Siddiqi et al., 2014) to clonally label tumor clones. The multicolor 
clonal labeling makes this animal model a useful tool for in vivo tumor imaging.  In vivo tumor 
imaging can be used to study many fundamental questions in tumor biology such as primary 
tumor growth, tumor cell motility and invasion, metastatic seeding and colonization, 
angiogenesis, and the interaction between the tumor and its microenvironment (Hoffman, 2005). 
Previous in vivo imaging studies, from whole body or direct view imaging using epifluorescent 
microscope (Yamamoto et al., 2011; Yang et al., 2000; Yang et al., 2002) to two photon 
microscopy imaging (Barretto et al., 2011; Madden et al., 2013),    fluorescently labeled tumor 
cells lines were used to generate tumor. However those orthotopic xenograft mouse models are 
not regarded to entirely resemble human tumors (Dai and Holland, 2001). This multicolor tumor 
model described here resembled human tumor histology thus can recapitulate human tumor cells 
behavior. It can be used not only in in vivo imaging but also in experiments that require 
visualization of tumor clonality. The establishment of the somatic engineered rat multicolor brain 
tumor model (Figure 3-1) will greatly facilitate and play an important role in in vivo tumor 
imaging. 
In utero electroporation shows high multiple plasmids co-transfection efficiency(Chen and 
LoTurco; Siddiqi et al.), and I have shown here as many as 7 plasmids cotransfection had been 
achieved (Fig 3).  Addition of Ngn2 or NeuroD1 to HRasV12/AKT mix induced a substantial 
change in the cytological appearance and the immunhistochemical pattern of resulting tumors, i.e. 
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ATRT like tumor formation demonstrating that piggyBac IUE tumor model should be a valuable 
platform for screening for gene therapy target as well as validating genes selected from forward 
genetic studies. Certainly, the role of respective genes needs to be assessed in respective human 
brain tumors. By addition of luciferase expressing plasmid to tumor inducing plasmid mixture, 
this system can easily be adapted to monitor tumor progression in vivo using bioluminescence 
imaging (Bhang et al., 2011; Uhrbom et al., 2004) which will make this system a valuable tool 
for high throughput anti-cancer drug screening.  
It is unclear that whether different tumor types or subtypes come from different neural 
progenitor population or tumors generated from different subsets of neural progenitors have 
different behaviors.  As mentioned above, piggyBac IUE allows for labeling of neural progenitor 
subpopulations. Therefore, now it is feasible to express oncogenes in lineage of subsets of neural 
progenitors and evaluate their contribution to tumorigenesis.  We have shown that astrocytes 
from the GLAST+ progenitors have larger clonal clusters than astrocytes from Nestin+ 
progenitors (Siddiqi et al., 2014). It is reasonable to ask are astrocytes in GLAST+ progenitor  
lineage more susceptible  to tumor induction? Are tumors induced from astrocytes in GLAST+ 
progenitor lineage more malignant? These questions can be addressed by selectively expressing 
oncogenes in specific cell types in the lineage of neural progenitor subpopulations using 
piggyBac IUE. 
One pitfall for using promoter fragment is that it sometimes cannot recapitulate endogenous 
promoter element activity. This is true with the mouse GFAP and rat MBP promoter fragments 
used in this dissertation (Figure 3-2). Even though, they showed enriched labeling of astrocytes 
and oligodendrocytes respectively, both promoters can label small fraction of other cell types. 
One solution to this is to use conditional piggyBac donor or helper plasmid in which transgene of 
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interest or PBase is flanked by loxP sites or FRT sites and transgenic mouse Cre or Flip lines. 
This allows genomic integration and/or transgene expression in specific cell types in radial glia 
subpopulations designated by transgenic mouse lines.  
 
Sources of inter tumor heterogeneity 
Cancers are highly heterogeneous. For instance, a single cancer type non small cell lung 
cancer, determined by cellular morphology, has over 15 subtype genomic signatures (Huang et 
al., 2014). There has been increasing appreciation of inter tumor heterogeneity being responsible 
for differential responses for cancer therapy. Understanding the sources of this heterogeneity will 
greatly help design effective targeted therapy and increase cancer patients’ prognosis.  
I have shown that in CNS oncogenic insults happening in distinct cell populations and/or 
molecular context can lead to different tumor types, supporting the notion that both cell of origin 
and genetic mutation contribute to inter tumor heterogeneity. It is more and more clear that cell 
of origin and genetic mutations intertwine and contribute to tumor heterogeneity. Glial cells 
and/or glial cell progenitors are long thought to be the cell of origin for glioma. Experimental 
evidences haven shown that OPCs can serve as cell of origin for proneural GBMs(Liu et al., 
2011). Direct comparison of gene expression profile of different GBM subtypes with molecular 
profile of different CNS cells populations showed that different GBM subtypes are reminiscent 
of distinct neural cell types and some mutations are associated with certain GBM 
subtypes(Verhaak et al., 2010). For example, the Proneural class was highly enriched with the 
oligodendrocytic signature but not the astrocytic signature, whereas the Classical group was 
strongly associated with the murine astrocytic signature. NF1 mutations predominantly occurred 
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in Mesenchymal subtype, whereas PDGFR and IDH1 alterations are the two major features of 
Proneural subtype. Focal EGFR alterations define Classical GBMs (Verhaak et al., 2010). Future 
experiments are needed to test, for example, whether Proneural GBM can be induced by 
introducing EGFR mutant in oligodendrocytes. 
Another example is breast cancer. Comprehensive gene expression profiling of large sets of 
breast cancer patients revealed 5 major subtypes: basal like, luminal A, luminal B, Her2
+
/ER
-
 
and normal breast like (Polyak, 2007, 2011)It is likely that there are multiple pathways to 
develop each type of tumor. Different tumor subtype might be caused by tumor specific genetic 
and epigenetic events occurring in distinct cells serving as cell of origin (Polyak, 2007, 2011). 
Lung cancer is the leading cause of cancer death worldwide. There are two main lung cancer 
subgroups based on histopathology classification: non small cell lung cancer (NSCLC) and small 
cell lung cancer (SCLC). The cell of origin for human lung cancers remains largely unknown. It 
is speculated that these different tumor subclasses arise from distinct cells of origin localized 
within a defined regional compartment/microenvironment (Sutherland and Berns, 2010). As 
many as 15 mutations have been observed in non small cell lung cancer patients including KRas, 
EGFR, PI3KCA, etc (Huang et al., 2014). It is reasonal to think that the variety of genetic 
mutaions and different cell of origins interact and contribute to lung cancer diversity. However, 
experimental evidences are still needed. 
 
Applications of CRISPR/Cas9 IUE in brain development and modeling CNS tumors 
CRISPR/Cas9 knocks out gene expression by inducing random mutations through the error 
prone NHEJ DNA repair pathway. DSB will be repaired through homology directed repair 
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pathway if the repair template is present.  By supplying a suitable DNA repair template bearing 
desired mutations together with CRISPR/Cas9, point mutations can be introduced into specific 
genomic locus through HDR repair pathway.  Many CNS disorders are caused by somatic 
mutations; therefore CRISPR-IUE approach provides a platform to model somatic CNS 
disorders. However, since HDR related enzyme mainly express at G2 phase of cell cycle, 
genomic engineering using HDR might not be  feasible in post mitotic cells, such as neurons. 
Conditional or inducbile CRISPR construct in which the Cas9 expression is gated by Cre 
recombinase would be very valuable in experiments that require cell type specific genetic 
manipulations. By combining conditional CRISPR construct and cell type specific Cre mouse 
lines, cell type specific genome engineering can be achieved.  This combination will maxmize 
the utility of both approach.  
DNA transposons including piggyBac, mediate random insertion. Many efforts have been 
made to direct site specific integration of transposons.  Site specific integration has been 
achieved using DNA transposase fused to DNA binding domains of transcription factors(Wang 
et al., 2012), zinc finger proteins (ZFPs) (Kettlun et al., 2011; Yant et al., 2007) and 
TALEs(Owens et al., 2013). Since gRNA is much easier to produce than ZFPs and TALEs, 
CRISPR-PBase fusion will be powerful in directing site specific integration mediated by 
piggyBac. Furthermore, transposon mediated integration can also be used for genome 
engineering and transposition process is independent of NHEJ and HDR DNA repair pathway. 
CRISPR-piggyBac system offers an alternative and complementary approach for targeted 
genome engineering.   
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Appendix I Supplementary Material for Chapter 3 
Supplementary Figure 3-1 Additional immunohistopathological features of GBM induced 
by PBCAG-HRasV12/AKT or PBGFAP-HRasV12/AKT.  
 
(A) Fibrillary and gemistocytic  
elements (H&E) in PBCAG-HRasV12/AKT induced tumor. (B) PBCAG-HRasV12/AKT 
induced tumor showed diffusely infiltrating pattern (H&E).  (C) Pleomorphism of tumor cells 
and mitotic activity (H&E) in PBCAG-HRasV12/AKT induced tumor. (D) Brisk mitotic activity 
in PBGFAP-HRasV12/AKT induced tumor. Black arrows indicate mitoses (H&E). 
Scale bar: 100µm in A, B and D; 50µm in C and E. 
 Supplementary Figure 3-2 Tumor cells can form tumor spheres in vitro 
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(A) 10x bright field image of tumor spheres. (B-C) Examples of tumor sphere in high 
magnification. B, bright filed image. C, fluorescent image. Scale bar: 300 µm in A and 200 µm 
in B and C. 
 
 
 
Supplementary Figure 3-3 Additional immunohistopathological features of ATRT like 
tumor induced by CAG-Ngn2 and PBCAG-HRasV12/AKT. 
 
 
(A) Process rich and epitheloid portions of the tumor (H&E).  Black arrow indicates necrotic 
area.  (B) Reticulin fiber staining – areas of the tumors with a rather dense fiber network are 
intermingled with those that lack this feature.  (C) Tumor cells with MAP2c positive processes. 
(D) Tumor cells with GFAP positive processes (black arrow). (E) Clusters of synaptophysin 
positive tumor cells. Black arrow indicates perisomatic expression pattern. Scale bar: 100µm in 
A, C and E 50µm in B and D. 
 
 
Supplementary Figure 3-4 Additional immunohistopathological features of ATRT like 
tumor induced by PBCAG-NeuroD1 and PBCAG-HRasV12/AKT 
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(A) Reticulin fiber staining - areas with some fiber network.  (B) Tumor cells with GFAP 
positive processes.  (C) Clusters of synaptophysin positive tumor cells.  (D) MAP2c positive 
cells and processes.  Scale bar: 100µm in A-D. 
 
Supplementary Figure 3-5 Additional immunohistopathological features of ATRT like 
tumor induced by PBCAG-NeuroD1 and PBCAG-HRasV12/AKT 
 
 
(A) Extensive necrosis in the tumor. Note the few layers of vital tumor cells around a blood 
vessel (black arrow) surrounded by large necrotic areas. (B)Strong and diffuse expression pattern 
of MAP2c.  (C) Strong expression of GFAP by a subset of tumor cells, some showed process 
rich astroglial morphology and others showed rhabdoid morphologies. Scale bar: 100µm in A-C. 
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Supplementary Figure 3-6 Gene expression profile of ATRT like tumors 
 
A panel of 7 genes was used to profile ATRT like tumors and qPCR results were shown here.  6 
out of 7 genes profiled showed significant up regulation. Error bar indicates standard error of 
mean (SEM). 
 
Supplementary Table 1 Primer sequence for qRT-PCR and SURVEYOR assay 
 
Name  Sequence 
DLL3 left ggtgacatgcgcagatggac 
DLL3 right  gaggccgccattctgacaag 
NKX2-2 left gccagcctcatccgtctcac 
NKK2-2 right  aagaccggcactgccacac 
SOX2 left  tccatgaccagctcgcagac 
SOX2 right ctggcctcggacttgaccac 
ERBB3 left  ccacgtgacaggctctgagg 
ERBB3 right gctgcgaatggtaggcactg 
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OLIG2 left  agcacctcctcgtccacgtc 
OLIG2 right tccatggcgatgttgaggtc 
FBXO3 left tcctgagaaggcctgtcagttg 
FBXO3 right  tgtggtgcagctggtgtattc 
GABRB2 left  aagatgcgcctggatgtcaac 
GABRB2 right  aggcaagcattgtgctcctg 
SNCG left  ccgaggcagctgagaagacc 
SNCG right  tcggtggccactgtgttgac 
MBP left  ggctacggaggcagagcttc 
MBP right  ccagagcggctgtctcttcc 
FGFR3 left  cagtgacgctctgccgtctg 
FGFR3 right tccggacgagaggtgtgttg 
PDGFA left  tacctcggagccaggtggac 
PDGFA right  accttgacactgcggtggtg 
EGFR left  ccacgtcacggactccactc 
EGFR right  cctctgtcaggacgctggtg 
AKT2 left  cttgcactcgacggatgtgg 
AKT2 right  cctcaggcgccaagtactcc 
NES left  agcagcgaggctctggaatg 
NES right  ggctgtcagtgctgcctgtg 
CASP1 left  ttcctggaccgagtggttc 
CASP1 right  ggcaagacgtgtacgagtgg 
CASP4 left  gcatgagccatgtggagaagg 
CASP4 right  gagcaggcatgtatccggaag 
CHI3L1 left ggatctcgcctggctctacc 
CHI3L1right  ctgacacggcagcactgagc 
TRADD left  actggagttgcgtgctggtg 
TRADD right  tccagctccgcgagttcttc 
TLR2 left  cctggtccatgtcctggttg 
TLR2 right  agtgcggcctggtgacactc 
TLR4 left  tcgagccagaatgaggactgg 
TLR4 right  ttggcagcaatggctacacc 
DNMT1 left  ggcgatgtggagatgctgtg 
DNMT1 right  ggaagaaccgaggccggtag 
TOP1 left acttggctggtctcctggac 
TOP1 right  tcttcagtcgccgagcagtc 
ABL1 left  cctgccgtctgctggtaagc 
ABL1 right gcggcctcctcagtcttcttc 
BOP1 left  tcggccaagagaccttcagc 
BOP1 right  cctcaatgtgccgtcgtctg 
Pla2g7 left AGCTCACCTTGCAGGATGTC 
Pla2g7 right TGTGATCCGGGAGAACTCTG 
Il5ra left ggcttgttggcaaggatg 
II5ra Right gagtgaacagctgatccaagg 
Tm4sf1 left ATCACGGGATCTGGCTACTG 
125 
 
Tm4sf1 Right AGTCACATGCCACTCCACAA 
SPP1 left TTGGCTTACGGACTGAGGTC 
SPP1 right GTTTCCACGCTTGGTTCATC 
Anxa1 left CCAGCTCAGTTTGATGCAGA 
Anxa1 right TCCAGATGTGTCCGAAGTGA 
Slc9a2 left AAGCTCACGCCAGGAGAAAT 
Slc9a2 right CTCGCGGTTTAAGCTGTTGT 
Dynap left GACACAGTGCGGCTGTAGG 
Dynap right GTCTGTGTGAACGACGATGG 
P53 left ACAGCGTGGTGGTACCGTAT 
P53 right ACAGGCACAAACACGAACCT 
 
P53 SURVEYOR assay primer 
P53 forward: ATGGAGGATTCACAGTCGGA 
P53 reverse: CCC ACT TTC TTG ATC ATT GG 
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Appendix II Supplementary Material for Chapter 4 
Supplementary Figure 4 - 1 
 
A, gRNAs targeting PTEN exon 6 and 8 introduced mutations at PTEN locus in vitro 
B, gRNA targeting PTEn exon 6 introduced mutations at PTEN locus in vivo 
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Supplementary Figure 4-2  
 
A, gRNAs targeting P53 E6 and NF1 E1 induced mutations at targeted genomic locus in 
neuroblastoma cells. 
B, gRNA targeting NF1 E1 abolished NF1 expression in neurons. 
C, gRNA targeting P53 E6 abolished P53 expression in neurons. 
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Supplementary Figure 4-3 
 
A-H, High magnification of representative images of high magnification brains transfected with 
CRISPR constructs.   Note the increased cell density in brains transfected with pX330-NF1  
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Supplementary Figure4-4 
 
A, In vivo SURVEYOR assay using tumor genomic DNA 
B, Representative sequences of mutated alleles identified at PTEN locus in induced tumors and 
corresponding protein sequences.  Translated protein sequences were shown below the DNA 
sequences. Guide sequence is shown in green. PAM is underlined. Dashes, deleted bases; red 
bases, insertion. Mutated amino acids are shown in red and underlined. 
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